Cancer Research and Treatment

Original Articles

Is Colonoscopy Alone Adequate for Surveillance in Stage I Colorectal Cancer?: Seijong Kim, Jung Kyong Shin, Yoonah Park, Jung Wook Huh, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Yong Beom Cho; Received June 4, 2024 Accepted October 2, 2024 Published online October 4, 2024; DOI: https://doi.org/10.4143/crt.2024.526 [Epub ahead of print]

Abstract PDF: Purpose
While colonoscopy is the standard surveillance tool for stage I colorectal cancer according to National Comprehensive Cancer Network guidelines, its effectiveness in detecting recurrence is debated. This study evaluates recurrence risk factors and patterns in stage I colorectal cancer to inform comprehensive surveillance strategies.
Materials and Methods
A retrospective analysis of 2,248 stage I colorectal cancer patients who underwent radical surgery at Samsung Medical Center (2007-2018) was conducted. Exclusions were based on familial history, prior recurrences, preoperative treatments, and inadequate data. Surveillance included colonoscopy, laboratory tests, and computed tomography (CT) scans.
Results
Stage I colorectal cancer patients showed favorable 5-year disease-free survival (98.3% colon, 94.6% rectum). Among a total of 1,467 colon cancer patients, 26 (1.76%) experienced recurrence. Of the 781 rectal cancer patients, 47 (6.02%) experienced recurrence. Elevated preoperative carcinoembryonic antigen levels and perineural invasion were significant recurrence risk factors in colon cancer, while tumor budding was significant in rectal cancer. Distant metastasis was the main recurrence pattern in colon cancer (92.3%), while rectal cancer showed predominantly local recurrence (50%). Colonoscopy alone detected recurrences in a small fraction of cases (3.7% in colon, 14.9% in rectum).
Conclusion
Although recurrence in stage I colorectal cancer is rare, relying solely on colonoscopy for surveillance may miss distant metastases or locoregional recurrence outside the colorectum. For high-risk patients, we recommend considering regular CT scans alongside colonoscopy. This targeted approach may enable earlier recurrence detection and improve outcomes in this subset while avoiding unnecessary scans for the low-risk majority.

499 View
32 Download

Pediatric cancer

Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study: Tingting Chen, Chenggong Zeng, Juan Wang, Feifei Sun, Junting Huang, Jia Zhu, Suying Lu, Ning Liao, Xiaohong Zhang, Zaisheng Chen, Xiuli Yuan, Zhen Yang, Haixia Guo, Liangchun Yang, Chuan Wen, Wenlin Zhang, Yang Li, Xuequn Luo, Zelin Wu, Lihua Yang, Riyang Liu, Mincui Zheng, Xiangling He, Xiaofei Sun, Zijun Zhen; Cancer Res Treat. 2024;56(4):1252-1261. Published online May 28, 2024; DOI: https://doi.org/10.4143/crt.2024.104

Abstract PDF Supplementary Material PubReader ePub: Purpose
The risk stratification of pediatric anaplastic large cell lymphoma (ALCL) has not been standardized. In this study, new risk factors were included to establish a new risk stratification system for ALCL, and its feasibility in clinical practice was explored.
Materials and Methods
On the basis of the non-Hodgkin’s lymphoma Berlin–Frankfurt–Munster 95 (NHL-BFM-95) protocol, patients with minimal disseminated disease (MDD), high-risk tumor site (multiple bone, skin, liver, and lung involvement), and small cell/lymphohistiocytic (SC/LH) pathological subtype were enrolled in risk stratification. Patients were treated with a modified NHL-BFM-95 protocol combined with an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).
Results
A total of 136 patients were enrolled in this study. The median age was 8.8 years. The 3-year event-free survival (EFS) and overall survival of the entire cohort were 77.7% (95% confidence interval [CI], 69.0% to 83.9%) and 92.3% (95% CI, 86.1% to 95.8%), respectively. The 3-year EFS rates of low-risk group (R1), intermediate-risk group (R2), and high-risk group (R3) patients were 100%, 89.5% (95% CI, 76.5% to 95.5%), and 67.9% (95% CI, 55.4% to 77.6%), respectively. The prognosis of patients with MDD (+), stage IV cancer, SC/LH lymphoma, and high-risk sites was poor, and the 3-year EFS rates were 45.3% (95% CI, 68.6% to 19.0%), 65.7% (95% CI, 47.6% to 78.9%), 55.7% (95% CI, 26.2% to 77.5%), and 70.7% (95% CI, 48.6% to 84.6%), respectively. At the end of follow-up, one of the five patients who received maintenance therapy with VBL relapsed, and seven patients receiving anaplastic lymphoma kinase inhibitor maintenance therapy did not experience relapse.
Conclusion
This study has confirmed the poor prognostic of MDD (+), high-risk site and SC/LH, but patients with SC/LH lymphoma and MDD (+) at diagnosis still need to receive better treatment (ClinicalTrials.gov number, NCT03971305).

1,389 View
84 Download

Lung and Thoracic cancer

Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy: Dowook Kim, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee, Suzy Kim, Tae Min Kim, Jin-Soo Kim, Byoung Hyuck Kim; Cancer Res Treat. 2024;56(2):430-441. Published online November 6, 2023; DOI: https://doi.org/10.4143/crt.2023.931

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to compare the failure patterns before and after the introduction of immunotherapy and to determine the role of thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) treatment.
Materials and Methods
We retrospectively reviewed 294 patients with ES-SCLC, of which 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune checkpoint inhibitor (ICI group). We performed propensity-score matching (PSM) to compare each treatment group.
Results
The median follow-up duration was 10.4 months. At the first relapse, in the cohort showing objective response, the proportion of cases showing intrathoracic progression was significantly lower in the TRT group (37.8%) than in the chemotherapy-alone (77.2%, p < 0.001) and the ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed benefits related to intrathoracic progression-free survival (PFS) in comparison with ICI in patients with less than two involved extrathoracic sites (p=0.008) or without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. After PSM, the TRT group showed significantly better intrathoracic PFS than both chemotherapy-alone and ICI groups (p < 0.001 and p=0.04, respectively), but showed no significant benefit in terms of PFS and overall survival in comparison with the ICI group (p=0.17 and p=0.31, respectively).
Conclusion
In ES-SCLC, intrathoracic progression was the most dominant failure pattern after immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be considered a useful treatment strategy for locoregional control.

Citations

Citations to this article as recorded by

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial
Łukasz Kuncman, Jacek Fijuth, Damian Tworek, Ewa Sierko, Paweł Cisek, Michał Masłowski, Maja Lisik-Habib, Magdalena Orzechowska, Katarzyna Galwas-Kliber, Adam Antczak, Izabela Chmielewska, Barbara Ziółkowska, Marta Kurczewska-Michalak, Wojciech Kuźnicki,
BMC Cancer.2025;[Epub] CrossRef
Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study
Meiling Sun, Huaijun Ji, Fang Deng, Jingyi Li, Ning Xu, Yu Li
BMC Cancer.2024;[Epub] CrossRef

3,596 View
183 Download
2 Web of Science
2 Crossref

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma: Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim; Cancer Res Treat. 2024;56(1):104-114. Published online July 24, 2023; DOI: https://doi.org/10.4143/crt.2023.728

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the clinical impact of genomic and pathway alterations in stage I epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high recurrence rate despite complete surgical resection.
Materials and Methods
Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing. We analyzed 11 canonical oncogenic pathways and determined the number of pathway alterations (NPA). Survival analyses were performed based on co-occurring alterations and NPA in three patient groups: all patients, patients with International Association for the Study of Lung Cancer (IASLC) pathology grade 2, and patients with recurrent tumors treated with EGFR–tyrosine kinase inhibitor (TKI).
Results
In the univariate analysis, pathological stage, IASLC grade, TP53 mutation, NPA, phosphoinositide 3-kinase pathway, p53 pathway, and cell cycle pathway exhibited significant associations with worse recurrence-free survival (RFS). Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS. Multivariate analysis revealed that pathologic stage, IASLC grade, and cell cycle pathway alteration were independent poor prognostic factors for RFS (p=0.002, p < 0.001, and p=0.006, respectively). In the grade 2 subgroup, higher NPA was independently associated with worse RFS (p=0.003). Additionally, in patients with recurrence treated with EGFR-TKIs, co-occurring TP53 mutations were linked to shorter progression-free survival (p=0.025).
Conclusion
Genomic and pathway alterations, particularly cell cycle alterations, high NPA, and TP53 mutations, were associated with worse clinical outcomes in stage I EGFR-mutant lung adenocarcinoma. These findings may have implications for risk stratification and the development of new therapeutic strategies in early-stage EGFR-mutant lung cancer patients.

Citations

Citations to this article as recorded by

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Masahiro Shimada, Masahiko Ando, Yasu
Investigational New Drugs.2025;[Epub] CrossRef

3,130 View
202 Download
1 Web of Science
1 Crossref

Breast cancer

Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy: Dowook Kim, Jin Ho Kim, In Ah Kim, Ji Hyun Chang, Kyung Hwan Shin; Cancer Res Treat. 2023;55(2):592-602. Published online October 11, 2022; DOI: https://doi.org/10.4143/crt.2022.998

Abstract PDF Supplementary Material PubReader ePub

Purpose
The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC.
Materials and Methods
We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT.
Results
The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03).
Conclusion
PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.

Citations

Citations to this article as recorded by

Analysis of Individualized Silicone Rubber Bolus Using Fan Beam Computed Tomography in Postmastectomy Radiotherapy: A Dosimetric Evaluation and Skin Acute Radiation Dermatitis Survey
Xue-mei Chen, Chen-di Xu, Li-ping Zeng, Xiao-tong Huang, Ao-qiang Chen, Lu Liu, Liu-wen Lin, Le-cheng Jia, Hua Li, Xiao-bo Jiang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Oncological outcomes of stage I–II breast cancer treatment after subcutaneous/skin-sparing mastectomies with reconstruction
E. A. Rasskazova, A. D. Zikiryakhodzhaev
MD-Onco.2024; 4(3): 37. CrossRef
Effectiveness of mat pilates on fatigue in women with breast cancer submitted to adjuvant radiotherapy: randomized controlled clinical trial
Daniele Medeiros Torres, Kelly de Menezes Fireman, Erica Alves Nogueira Fabro, Luiz Claudio Santos Thuler, Rosalina Jorge Koifman, Anke Bergmann, Sabrina da Silva Santos
Supportive Care in Cancer.2023;[Epub] CrossRef
The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review
Giulia Ferrarazzo, Alberto Nieri, Emma Firpo, Andrea Rattaro, Alessandro Mignone, Flavio Guasone, Augusto Manzara, Giuseppe Perniciaro, Stefano Spinaci
Current Oncology.2023; 30(10): 8703. CrossRef

5,702 View
214 Download
5 Web of Science
5 Crossref

Lung and Thoracic cancer

Predictive Value of Interstitial Lung Abnormalities for Postoperative Pulmonary Complications in Elderly Patients with Early-stage Lung Cancer: Won Gi Jeong, Yun-Hyeon Kim, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Kum Ju Chae, Hye Mi Park; Cancer Res Treat. 2022;54(3):744-752. Published online September 28, 2021; DOI: https://doi.org/10.4143/crt.2021.772

Abstract PDF Supplementary Material PubReader ePub

Purpose
Identifying pretreatment interstitial lung abnormalities (ILAs) is important because of their predictive value for complications after lung cancer treatment. This study aimed to assess the predictive value of ILAs for postoperative pulmonary complications (PPCs) in elderly patients undergoing curative resection for early-stage non-small cell lung cancer (NSCLC).
Materials and Methods
Elderly patients (age ≥ 70 years) who underwent curative resection for pathologic stage I or II NSCLC with normal preoperative spirometry results (pre-bronchodilator forced expiratory volume in 1 s to forced vital capacity [FVC] ratio > 0.70 and FVC ≥ 80% of the predicted value) between January 2012 and December 2019 were retrospectively identified. Univariable and multivariable regression analyses were performed to assess risk factors for PPCs. The Kaplan–Meier method and log-rank test were used to analyze the relationship between ILAs and postoperative mortality. One-way analysis of variance was performed to assess the correlation between ILAs and hospital stay duration.
Results
A total of 262 patients (median age, 73 [interquartile range, 71–76] years; 132 male) were evaluated. A multivariable logistic regression model revealed that, among several relevant risk factors, fibrotic ILAs independently predicted both overall PPCs (adjusted odds ratio [OR], 4.84; 95% confidence interval [CI], 1.35–17.38; p=0.016) and major PPCs (adjusted OR, 8.72; 95% CI, 1.71–44.38; p=0.009). Fibrotic ILAs were significantly associated with higher postoperative mortality and longer hospital stay (F=5.21, p=0.006).
Conclusion
Pretreatment fibrotic ILAs are associated with PPCs, higher postoperative mortality, and longer hospital stay.

Citations

Citations to this article as recorded by

Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients
Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim
Journal of Computer Assisted Tomography.2024; 48(3): 406. CrossRef
Interstitial Lung Abnormalities
Noriaki Wada, Gary M. Hunninghake, Hiroto Hatabu
Clinics in Chest Medicine.2024; 45(2): 433. CrossRef
Incidence and risk factors of pulmonary complications after lung cancer surgery: A systematic review and meta-analysis
Ting Deng, Jiamei Song, Jinmei Tuo, Yu Wang, Jin Li, Lorna Kwai Ping Suen, Yan Liang, Junliang Ma, Shaolin Chen
Heliyon.2024; 10(12): e32821. CrossRef
Survival impact of fibrotic interstitial lung abnormalities in resected stage IA non-small cell lung cancer
Won Gi Jeong, Yun-Hyeon Kim
The British Journal of Radiology.2023;[Epub] CrossRef
Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer
Yoon Joo Shin, Jeong Geun Yi, Mi Young Kim, Donghee Son, Su Yeon Ahn
Journal of Clinical Medicine.2023; 12(21): 6858. CrossRef
Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
Pengfei Wang, Li Zhang, Qian Guo, Lifen Zhao, Yanyan Hao
Open Medicine.2023;[Epub] CrossRef
Clinical implication of interstitial lung abnormality in elderly patients with early‐stage non‐small cell lung cancer
Seong Woo Cho, Won Gi Jeong, Jong Eun Lee, In‐Jae Oh, Sang Yun Song, Hye Mi Park, Hyo‐Jae Lee, Yun‐Hyeon Kim
Thoracic Cancer.2022; 13(7): 977. CrossRef

6,919 View
167 Download
8 Web of Science
7 Crossref

Hematologic malignancy

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study: Yu Ri Kim, Soo-Jeong Kim, Hye Sun Lee, Soyoung Jeon, Hyunsoo Cho, Haerim Chung, Ji Eun Jang, June-Won Cheong, Yoo Hong Min, Jin Seok Kim; Cancer Res Treat. 2022;54(2):613-620. Published online August 5, 2021; DOI: https://doi.org/10.4143/crt.2021.270

Abstract PDF PubReader ePub

Purpose
Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24.
Materials and Methods
Patients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24.
Results
Overall, 153 patients were evaluated, and 51 patients (33.3%) achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p < 0.001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population. After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.094). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p < 0.001).
Conclusion
Patients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.

Citations

Citations to this article as recorded by

Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS
Zheng Cao, Xiaojun Wang, Xuemin Xue, Xiaoli Feng
Annals of Hematology.2024; 103(3): 869. CrossRef
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments
Sarit Assouline, Adriana Wiesinger, Clare Spooner, Jelena Jovanović, Max Schlueter
Critical Reviews in Oncology/Hematology.2022; 175: 103711. CrossRef

6,001 View
136 Download
2 Web of Science
2 Crossref

Breast cancer

Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02): Yeon Joo Kim, Yeon-Joo Kim, Yong Bae Kim, Ik Jae Lee, Jeanny Kwon, Kyubo Kim, Jihye Cha, Myungsoo Kim, In Young Jo, Jung Hoon Kim, Jaehyeon Park, Jin Hee Kim, Juree Kim, Kyung Hwan Shin, Su Ssan Kim; Cancer Res Treat. 2022;54(2):478-487. Published online July 12, 2021; DOI: https://doi.org/10.4143/crt.2021.632

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit from PORT.
Materials and Methods
This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively.
Results
The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, ≤ 5 metastases, and non-TNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3.
Conclusion
PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.

Citations

Citations to this article as recorded by

Letter to the editor for the article“Tumor margin irregularity degree is an important preoperative predictor of adverse pathology for clinical T1/2 renal cell carcinoma and the construction of predictive model”
Yaping Miao, Lexin Wang, Ping Chen, Jiaan Lu, Guanhu Yang, Hao Chi
World Journal of Urology.2024;[Epub] CrossRef
The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
Tian Yang, Xiaorong Zhong, Jun Wang, Zhongzheng Xiang, Yuanyuan Zeng, Siting Yu, Zelei Dai, Ningyue Xu, Ting Luo, Lei Liu
Cancer Medicine.2023; 12(7): 8112. CrossRef
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
Radiation Oncology.2023;[Epub] CrossRef
Machine learning predicts the prognosis of breast cancer patients with initial bone metastases
Chaofan Li, Mengjie Liu, Jia Li, Weiwei Wang, Cong Feng, Yifan Cai, Fei Wu, Xixi Zhao, Chong Du, Yinbin Zhang, Yusheng Wang, Shuqun Zhang, Jingkun Qu
Frontiers in Public Health.2022;[Epub] CrossRef
Factors Influencing Prognosis in Patients with De Novo Stage IV Breast Cancer: A Systematic Review and Meta-Analysis
Meilin Zhang, Zining Jin, Yingying Xu, Bo Chen, Jian Song, Muyao Li, Feng Jin, Ang Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef

7,352 View
171 Download
4 Web of Science
5 Crossref

Head and Neck cancer

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up: Lin Wang, Jingjing Miao, Huageng Huang, Boyu Chen, Xiao Xiao, Manyi Zhu, Yingshan Liang, Weiwei Xiao, Shaomin Huang, Yinglin Peng, Xiaowu Deng, Xing Lv, Weixiong Xia, Yanqun Xiang, Xiang Guo, Fei Han, Chong Zhao; Cancer Res Treat. 2022;54(1):118-129. Published online June 7, 2021; DOI: https://doi.org/10.4143/crt.2021.101

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was aimed to investigate long-term survivals and toxicities of early-stage nasopharyngeal carcinoma (NPC) in endemic area, evaluating the role of chemotherapy in stage II patients.
Materials and Methods
Totally 187 patients with newly diagnosed NPC and restaged American Joint Committee on Cancer/ International Union Against Cancer 8th T1-2N0-1M0 were retrospectively recruited. All received intensity-modulated radiotherapy (IMRT)±chemotherapy (CT) from 2001 to 2010.
Results
With 15.7-year median follow-up, 10-year locoregional recurrence-free survival, distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were 93.3%, 93.5%, 92.9% and 88.2%, respectively. Multivariable analyses showed cervical lymph nodes positive and pre-treatment prognostic nutritional index ≥ 52.0 could independently predict DMFS (p=0.036 and p=0.011), DSS (p=0.014 and p=0.026), and OS (p=0.002 and p < 0.001); Charlson comorbidity index < 3 points could predict DSS (p=0.011); age > 45 years (p=0.002) and pre-treatment lactate dehydrogenase ≥ 240 U/L (p < 0.001) predicted OS. No grade 4 late toxicity happened; grade 3 late toxicities included subcutaneous fibrosis (4.3%), deafness or otitis (4.8%), skin dystrophy (2.1%), and xerostomia (1.1%). No differences on survivals were shown between IMRT+CT vs. IMRT alone in stage II patients, even in T2N1M0 (p > 0.05). Unsurprising, patients in IMRT+CT had more acute gastrointestinal reaction, myelosuppression, mucositis, late ear toxicity, and cranial nerve injury (all p < 0.05) than IMRT alone group.
Conclusion
Superior tumor control and satisfying long-term outcomes could be achieved with IMRT in early-stage NPC with mild late toxicities. As CT would bring more toxicities, it should be carefully performed to stage II patients.

Citations

Citations to this article as recorded by

Retrospective analysis of 1539 nasopharyngeal carcinoma cases: chemotherapy should not be excluded for non-Asian patients with T1-2N1M0 stage
Xin-Yu Li, Chang-Ying Zhong, Hui-Xian Xu
Frontiers in Oncology.2025;[Epub] CrossRef
Genistein and chlorin E6-loaded versatile nanoformulation for remodeling the hypoxia-related tumor microenvironment and boosting photodynamic therapy in nasopharyngeal carcinoma treatment
Qiang Zhou, Quazi T. H. Shubhra, Peng Lai, Jiayi Shi, Chenhao Fang, Qian Guo, Wanqing Li, Rui Chen, Xinkun Shen, Lina Huang, Xiaojun Cai, Sen Lin
Advanced Composites and Hybrid Materials.2025;[Epub] CrossRef
Radiation oncology for the rhinologist
Helena Levyn, Fan Yang, Nancy Y. Lee
Current Opinion in Otolaryngology & Head & Neck Surgery.2024; 32(1): 5. CrossRef
Examining patient-reported late toxicity and its association with quality of life and unmet need for symptom management among nasopharyngeal cancer survivors: a cross-sectional survey
Victor C. W. Tam, Jerry C. F. Ching, Sindy S. T. Yip, Virginia H. Y. Kwong, Catherine P. L. Chan, Kenneth C. W. Wong, Shara W. Y. Lee
Frontiers in Oncology.2024;[Epub] CrossRef
Multifactorial clinical analysis of factors affecting necrosis of nasal septal mucosal flap after salvage surgery for recurrent nasopharyngeal carcinoma
Qilin Gong, Huaying Li, Hui Liu, Youyuan Shi
Scientific Reports.2024;[Epub] CrossRef
Long noncoding RNA LINC00173 induces radioresistance in nasopharyngeal carcinoma via inhibiting CHK2/P53 pathway
Jingjing Miao, Boyu Chen, Yunyun Xiao, Runda Huang, Xiao Xiao, Shunzhen Lu, Lu Zhang, Xuguang Wang, Ying Ouyang, Xiangfu Chen, Qiuyan Chen, Yanqun Xiang, Xiang Guo, Xiaowu Deng, Lin Wang, Haiqiang Mai, Chong Zhao
Cancer Gene Therapy.2023; 30(9): 1249. CrossRef
Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma
Chengcong Chen, Anbang Ren, Qi Yi, Jiazuo Cai, Muhammad Khan, Yunen Lin, Zhong Huang, Jie Lin, Jian Zhang, Wei Liu, Anan Xu, Yunhong Tian, YaWei Yuan, Ronghui Zheng
Clinical and Experimental Immunology.2023; 213(2): 221. CrossRef
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huageng Huang, Yuyi Yao, Xinyi Deng, Zongyao Huang, Yungchang Chen, Zhao Wang, Huangming Hong, He Huang, Tongyu Lin
International Journal of Oncology.2023;[Epub] CrossRef
Quality of life and swallowing outcomes after early proactive swallowing rehabilitation by either transcutaneous neuromuscular electrical stimulation or exercise‐based swallowing training in patients with nasopharyngeal carcinoma after radiotherapy
Peter K. M. Ku, Alexander C. Vlantis, Rita W. M. Wong, Thomas S. C. Hui, Thomas Law, Louisa K. Y. Ng, Eddy W. Y. Wong, W. T. Chang, David R. Johnson, Florence S. T. Mok, K. H. Wong, Victor Abdullah, Andrew van Hasselt, Kathy Y. S. Lee, Michael C. F. Tong
Laryngoscope Investigative Otolaryngology.2023; 8(6): 1532. CrossRef
Prognostic nutritional index and serum lactate dehydrogenase predict the prognosis of nasopharyngeal carcinoma patients who received intensity-modulated radiation therapy
Chunxia Zhang, Zhouwei Zhan, Yunxiang Fang, Yuanyuan Ruan, Mingan Lin, Zhisen Dai, Yanping Zhang, Shanshan Yang, Shuxiang Xiao, Bijuan Chen
Journal of Cancer Research and Clinical Oncology.2023; 149(20): 17795. CrossRef
A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang, Xiao-Dong Zhu
Frontiers in Oncology.2022;[Epub] CrossRef
Minimally Invasive Surgery for Early-Stage Nasopharyngeal Carcinoma
Jinping Liu, Zesheng Zeng, Dingting Wang, Gang Qin
Journal of Craniofacial Surgery.2022; 33(8): e834. CrossRef
External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma
Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam, Chi-Leung Chiang, Chun-Yin Edwin Wong, Ming-Chun Darren Poon, Macy Tong,
Cancers.2021; 13(17): 4286. CrossRef

7,165 View
174 Download
13 Web of Science
13 Crossref

Gastrointestinal cancer

Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection: Sujin Park, Sangjoon Choi, Yoon Ah Cho, Dong Hyun Sinn, Jong Man Kim, Cheol-Keun Park, Sang Yun Ha; Cancer Res Treat. 2020;52(4):1145-1152. Published online April 28, 2020; DOI: https://doi.org/10.4143/crt.2020.208

Abstract PDF Supplementary Material PubReader ePub

Purpose
Recently, the 8th edition staging system of the American Joint Committee on Cancer (AJCC) for hepatocellular carcinoma (HCC) was released, including a change in T category. We aimed to validate the new AJCC system.
Materials and Methods
The predictive value of the new AJCC was validated in comparison to the previous edition, in a total 1,008 patients who underwent curative resection for HCC as initial treatment.
Results
The 2-year area under the curve values for recurrence-free survival (RFS) and overall survival (OS) were comparable in the 7th and 8th editions. Stage migration was observed in 63 patients (6.3%); from T2 to T1a for 44 patients and from T3 to T4 for 19 patients. The RFS and OS were not different between T1a and T1b in the 8th edition. For solitary tumors ≤ 2 cm, those with microvascular invasion had lower RFS and OS values than those without although they were all classified as T1a in the 8th edition. Tumors involving a major branch of the portal or hepatic vein (T4 by the 8th edition and T3b by the 7th edition) had shorter RFS and OS than multifocal tumors, at least one of which was > 5 cm (T3 by the 8th edition and T3a by the 7th edition).
Conclusion
The AJCC 8th edition staging system for HCC showed comparable predictive performance to the 7th edition. It is desirable in a future revision to consider sub-stratification of solitary tumors ≤ 2 cm (T1a) depending on the presence of vascular invasion, which is not included in the 8th edition.

Citations

Citations to this article as recorded by

Improving Adherence of Young Male Patients with HBV Infection to the Regular Follow-Up via Mobile Healthcare Platform Might Be Cost-Effective to Decrease the Morbidity of Advanced Liver Cancer
Hao Liang, Min Yang, Dan Luo, Ya-Kun Wu
Patient Preference and Adherence.2024; Volume 18: 2581. CrossRef
Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance
Yi Zhang, Jun-Gang Zhang, Wei Yu, Lei Liang, Chun Wu, Cheng-Wu Zhang, Ya-Ming Xie, Dong-Sheng Huang, Ying Shi
Frontiers in Surgery.2023;[Epub] CrossRef
Advances in post-operative prognostic models for hepatocellular carcinoma
Ziqin He, Xiaomin She, Ziyu Liu, Xing Gao, Lu Lu, Julu Huang, Cheng Lu, Yan Lin, Rong Liang, Jiazhou Ye
Journal of Zhejiang University-SCIENCE B.2023; 24(3): 191. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer.2023; 23(1): 1. CrossRef
Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer
Yueh-Wei Liu, Wei-Feng Li, Fang-Ying Kuo, Hock-Liew Eng, Chih-Chi Wang, Chih-Che Lin, Chee-Chien Yong, Yi-Hao Yen
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma
Li Zhang, Guodong Pang, Jing Zhang, Zhenguo Yuan
Scientific Reports.2023;[Epub] CrossRef
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
Diwakar Suresh, Akshatha N. Srinivas, Akila Prashant, Suchitha Satish, Prashant Vishwanath, Suma M. Nataraj, Srinivas V. Koduru, Prasanna K. Santhekadur, Divya P. Kumar
Frontiers in Oncology.2023;[Epub] CrossRef
ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma
Yiyin Zhang, Jiaxi Cheng, Cheng Zhong, Qiming Xia, Yirun Li, Peng Chen, Xiaoxiao Fan, Qijiang Mao, Hui Lin, Defei Hong
Frontiers in Oncology.2022;[Epub] CrossRef
Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion
Yiwen Qiu, Yi Yang, Tao Wang, Shu Shen, Wentao Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience
Zehao Zheng, Renguo Guan, Yiping Zou, Zhixiang Jian, Ye Lin, Rongping Guo, Haosheng Jin
Journal of Inflammation Research.2022; Volume 15: 5089. CrossRef
CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma
Wang Zhang, Yipeng Wan, Yue Zhang, Qi Liu, Xuan Zhu
Cancer Management and Research.2022; Volume 14: 2691. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion
Er-lei Zhang, Qi Cheng, Zhi-yong Huang, Wei Dong
Frontiers in Oncology.2021;[Epub] CrossRef
Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy
Xinming Li, Xuchang Zhang, Zhipeng Li, Chuanmiao Xie, Shuping Qin, Meng Yan, Qiying Ke, Xuan Jin, Ting Lin, Muyao Zhou, Wen Liang, Zhendong Qi, Zhijun Geng, Xianyue Quan
Frontiers in Oncology.2021;[Epub] CrossRef
Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma
Linfeng Xu, Xingxing Jian, Zhenhao Liu, Jingjing Zhao, Siwen Zhang, Yong Lin, Lu Xie
Frontiers in Genetics.2021;[Epub] CrossRef
Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma
Ji Hae Nahm, Young Nyun Park
The Korean Journal of Gastroenterology.2021; 78(5): 268. CrossRef

8,731 View
155 Download
28 Web of Science
16 Crossref

Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System: Jong Woo Lee, Jae Hoon Lee, Yejong Park, Woohyung Lee, Jaewoo Kwon, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim; Cancer Res Treat. 2020;52(3):886-895. Published online March 12, 2020; DOI: https://doi.org/10.4143/crt.2020.023

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate the prognostic values of the 7th and 8th American Joint Committee on Cancer (AJCC) staging systems for patients with resected perihilar cholangiocarcinoma (PHCC).
Materials and Methods
A total of 348 patients who underwent major hepatectomy for PHCC between 2008 and 2015 were identified from a single center. Overall survival (OS) was estimated using the Kaplan-Meier method and compared across stage groups with the log-rank test. The concordance index was used to evaluate the prognostic predictability of the 8th AJCC staging system compared with that of the 7th.
Results
In the 8th edition, the stratification of each group of T classification improved compared to that in the 7th, as the survival rate of T4 decreased (T2, 31.2%; T3, 13.9%; T4, 15.1%; T1- T2, p=0.260; T2-T3, p=0.001; T3-T4, p=0.996). Both editions showed significant survival differences between each N category, except between N1 and N2 (p=0.063) in 7th edition. Differences of point estimates between the 8th and 7th T and N classification and overall stages were +0.028, +0.006, and +0.039, respectively (T, p=0.005; N, p=0.115; overall stage, p=0.005). In multivariable analysis, posthepatectomy liver failure, T category, N category, distant metastasis, histologic differentiation, intraoperative transfusion, and resection margin status were associated with OS.
Conclusion
The prognostic predictability of 8th AJCC staging for PHCC improved slightly, with statistical significance, compared to the 7th edition, but its overall performance is still unsatisfactory.

Citations

Citations to this article as recorded by

Postoperative factors predicting outcomes in patients with Perihilar cholangiocarcinoma undergoing curative resection—a 10-year single-center experience
Hasan Ahmad Al-Saffar, Nicolai Schultz, Peter Nørrgaard Larsen, Eva Fallentin, Gro Linno Willemoe, Diana Elena Renteria Ramirez, Lucas Alexander Knøfler, Hans-Christian Pommergaard
Scandinavian Journal of Gastroenterology.2025; 60(1): 73. CrossRef
The preoperative scoring system combining neutrophil/lymphocyte ratio and CA19-9 predicts the long-term prognosis of intrahepatic cholangiocarcinoma patients undergoing curative liver resection
Shilei Bai, Xiaodong Shi, Yizhe Dai, Huifeng Wang, Yong Xia, Jian Liu, Kui Wang
BMC Cancer.2024;[Epub] CrossRef
Preoperative factors predicting outcomes in patients with suspected perihilar cholangiocarcinoma referred for curative resection— a single-center 10-year experience
HA Al-Saffar, PN Larsen, N Schultz, TS Kristensen, DE Renteria, LA Knøfler, HC Pommergaard
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Evaluation of Four Lymph Node Classifications for the Prediction of Survival in Hilar Cholangiocarcinoma
Zhi-Peng Liu, Qing-Yi Zhang, Wei-Yue Chen, Yu-Yan Huang, Yan-Qi Zhang, Yi Gong, Yan Jiang, Jie Bai, Zhi-Yu Chen, Hai-Su Dai
Journal of Gastrointestinal Surgery.2022; 26(5): 1030. CrossRef
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry
Lynn E. Nooijen, Jesus M. Banales, Marieke T. de Boer, Chiara Braconi, Trine Folseraas, Alejandro Forner, Waclaw Holowko, Frederik J. H. Hoogwater, Heinz-Josef Klümpen, Bas Groot Koerkamp, Angela Lamarca, Adelaida La Casta, Flora López-López, Laura Izquie
Cancers.2022; 14(10): 2389. CrossRef
Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand
Chaiwat Aphivatanasiri, Prakasit Sa-Ngiamwibool, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Waritta Kunprom, Malinee Thanee, Piya Prajumwongs, Narong Khuntikeo, Attapol Titapun, Apiwat Jareanrat, Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Kulyad
Frontiers in Medicine.2022;[Epub] CrossRef
Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection
Gang Heng, Benqi Huang, Yanbing Shen, Dan wang, Zhen Lan, Yuxuan Yao, Jianxin Zhang, Jiankun Jia, Chengcheng Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Development and validation of preoperative magnetic resonance imaging-based survival predictive nomograms for patients with perihilar cholangiocarcinoma after radical resection: A pilot study
Jian Zhao, Wei Zhang, Cheng-Lin Fan, Jun Zhang, Fang Yuan, Si-Yun Liu, Fu-Yu Li, Bin Song
European Journal of Radiology.2021; 138: 109631. CrossRef
A Novel Nomogram Based on Log Odds of Metastatic Lymph Nodes to Predict Overall Survival in Patients With Perihilar Cholangiocarcinoma After Surgery
Wenbo Zou, Chunyu Zhu, Zizheng Wang, Xianglong Tan, Chenggang Li, Zhiming Zhao, Minggen Hu, Rong Liu
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Relevance of the Eighth Edition of TNM Classification for Resected Perihilar Cholangiocarcinoma
Hans-Michael Hau, Felix Meyer, Nora Jahn, Sebastian Rademacher, Robert Sucher, Daniel Seehofer
Journal of Clinical Medicine.2020; 9(10): 3152. CrossRef

7,236 View
163 Download
14 Web of Science
10 Crossref

Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow-up of Patients without Node Dissection: You-Na Sung, Minjeong Song, Jae Hoon Lee, Ki Byung Song, Dae Wook Hwang, Chul-Soo Ahn, Shin Hwang, Seung-Mo Hong; Cancer Res Treat. 2020;52(2):455-468. Published online October 17, 2019; DOI: https://doi.org/10.4143/crt.2019.271

Abstract PDF PubReader ePub

Purpose
The 8th edition of gallbladder cancer staging in the American Joint Committee on Cancer (AJCC) staging system changed the T and N categories.
Materials and Methods
In order to validate the new staging system, a total of 348 surgically resected gallbladder cancers were grouped based on the 8th edition of the T and N categories and compared with patients’ survival.
Results
Significant differences were noted between T1b-T2a (p=0.003) and T2b-T3 (p < 0.001) tumors, but not between Tis-T1a, T1a-T1b, and T2a-T2b tumors. However, significant survival differences were observed both by the overall and pair-wise (T1-T2, T2-T3) comparisons (all, p < 0.001) without dividing T1/T2 subcategories. When cases with ≥ 6 examined lymph nodes were evaluated, significant survival differences were observed among the entire comparison (p < 0.001) and pair-wise comparisons of N0-N1 (p=0.001) and N1-N2 (p=0.039) lesions. When cases without nodal dissection (NX) were additionally compared, significant survival differences were observed between patients with N0-NX (p=0.001) and NX-N1 (p < 0.001) lesions.
Conclusion
The T category in the 8th edition of the AJCC staging system did not completely stratify the prognosis of patients with gallbladder cancer. Modification by eliminating T subcategories can better stratify the prognosis. In contrast, the N category clearly determines patients’ survival with ≥ 6 examined lymph nodes. The survival time in patients of gallbladder cancers without nodal dissection is between N0 and N1 cases. Therefore, close postoperative followed up is recommended for those patients.

Citations

Citations to this article as recorded by

Intramucosal Extent as a Marker for Advanced Disease and Survival in Gallbladder Adenocarcinoma
Robert Naples, Breanna C. Perlmutter, Haiyan Lu, Daniela Allende, Chao Tu, Asif Hitawala, Pravallika Chadalavada, Vinay Padbidri, Abdo Haddad, Robert Simon, R. Matthew Walsh, Toms Augustin
The American Surgeon™.2024; 90(6): 1133. CrossRef
DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis
Sunwang Xu, Zhiqing Yuan, Cen Jiang, Wei Chen, Qiwei Li, Tao Chen
Advanced Science.2024;[Epub] CrossRef
Outcomes of patients with gallbladder cancer presenting with acute cholecystitis
Nunzio F Franco, Ngee-Soon Lau, Wai M Liu, Aadil Rahim, Mitali Fadia, Yu Jo Chua, Ankit Jain, Desmond Yip, Sivakumar Gananadha
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Case and Management Considerations of Low‐Grade Cystic Duct Stump Dysplasia after Laparoscopic Cholecystectomy
Claire Ufongene, Saran Kunaprayoon, Juan Mestre, Dimitrios Mantas
Case Reports in Surgery.2024;[Epub] CrossRef
Gallbladder Cancer
Giacomo C. Waller, Umut Sarpel
Surgical Clinics of North America.2024; 104(6): 1263. CrossRef
Robotic resection for gallbladder cancer: Superior lymphadenectomy does not equal better survival
Michela Fabricius, Amika Ekanem, Allison N. Martin
Surgery.2024; 176(4): 1016. CrossRef
Comparison of Prognostic Performance of 8th and 7th Edition of AJCC Staging System for Patients With Gallbladder Cancer Undergoing Curative Intent Surgery
Sameer Gupta, Abhishek Verma, Arun Chaturvedi, Puneet Prakash, Vijay Kumar, Sanjeev Misra, Naseem Akhtar, Shiv Rajan, Preeti Agarwal, Lynette Smith, Makayla Schissel, Chandrakanth Are
Journal of Surgical Oncology.2024;[Epub] CrossRef
Prognostic utility of the modified albumin-bilirubin score among patients undergoing curative-intent surgery for gallbladder cancer
Odysseas P. Chatzipanagiotou, Diamantis I. Tsilimigras, Giovanni Catalano, Andrea Ruzzenente, Federico Aucejo, Hugo P. Marques, Vincent Lam, Nazim Bhimani, Shishir K. Maithel, Itaru Endo, Minoru Kitago, Timothy M. Pawlik
Journal of Gastrointestinal Surgery.2024; 28(12): 2075. CrossRef
A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer
N. Begüm Öztürk, Artem Dadamyan, Laith H. Jamil
Healthcare.2024; 12(20): 2091. CrossRef
T1b gallbladder cancer: is extended resection warranted?
Montserrat Chavez, Xabier de Aretxabala, Hector Losada, Norberto Portillo, Felipe Castillo, Luis Bustos, Ivan Roa
HPB.2024;[Epub] CrossRef
Survival Predictors of Resectable Gallbladder Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database
Jisheng Zhu, Yunxiang Wu, Weidong Xiao, Yong Li
The American Surgeon™.2023; 89(5): 1629. CrossRef
Reappraisal of T1b gallbladder cancer (GBC): clinicopathologic analysis of 473 in situ and invasive GBCs and critical review of the literature highlights its rarity, and that it has a very good prognosis
Burcin Pehlivanoglu, Gizem Akkas, Bahar Memis, Olca Basturk, Michelle D. Reid, Burcu Saka, Nevra Dursun, Pelin Bagci, Serdar Balci, Juan Sarmiento, Shishir K. Maithel, Sudeshna Bandyopadhyay, Oscar Tapia Escalona, Juan Carlos Araya, Hector Losada, Michael
Virchows Archiv.2023; 482(2): 311. CrossRef
Subserosal vascular density predicts oncological features of T2 gallbladder cancer
Miho Akabane, Junichi Shindoh, Kei Kohno, Satoshi Okubo, Masaru Matsumura, Yutaka Takazawa, Masaji Hashimoto
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Standardized lymph node dissection for gallbladder cancer under laparoscopy: en-bloc resection technique
Jian Cheng, Jie Liu, Chang-Wei Dou, Zhong-Chun Xie, Bing-Fu Fan, Li-Ming Jin, Lei Liang, Cheng-Wu Zhang
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Development and validation of an online dynamic prognostic nomogram for incidental gallbladder adenocarcinoma patients without distant metastasis after surgery: a population-based study
Jie Chen, Yehong Han
Frontiers in Medicine.2023;[Epub] CrossRef
Effects of Cystic Duct Margin Involvement on the Survival Rates of Patients With Gallbladder Cancer: A Propensity Score-Matched Case-Control Study
Vasistha Jajal, Phani K Nekarakanti, Sugumaran K, Hirdaya Nag
Cureus.2023;[Epub] CrossRef
Laparoskopik Kolesistektomi Yapılan Hastalarda Rastlantısal Safra Kesesi Kanseri Sıklığı
Serkan ERKAN, Hakan YABANOĞLU
Harran Üniversitesi Tıp Fakültesi Dergisi.2023; 20(3): 593. CrossRef
Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital
Niharika Bisht, Nishant Lohia, Sankalp Singh, Arti Sarin, Abhishek Mahato, Dharmesh Paliwal, Indranil Sinha, Sharad Bhatnagar
World Journal of Nuclear Medicine.2023; 22(04): 276. CrossRef
Lymphadenectomy in gallbladder adenocarcinoma: Are we doing enough?
Marianna V. Papageorge, Susanna W.L. de Geus, Alison P. Woods, Sing Chau Ng, F. Thurston Drake, Andrea Merrill, Michael R. Cassidy, David McAneny, Jennifer F. Tseng, Teviah E. Sachs
The American Journal of Surgery.2022; 224(1): 423. CrossRef
Systematic review and meta-analysis of survival outcomes in T2a and T2b gallbladder cancers
Wasfi Alrawashdeh, Sivesh K. Kamarajah, Rohan R. Gujjuri, William A. Cambridge, Shailesh V. Shrikhande, Alice C. Wei, Mohamed Abu Hilal, Steve A. White, Sanjay Pandanaboyana
HPB.2022; 24(6): 789. CrossRef
Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406)
Ryota Higuchi, Hiroaki Ono, Ryusei Matsuyama, Yusuke Takemura, Shinjiro Kobayashi, Takehito Otsubo, Yuta Abe, Itaru Endo, Minoru Tanabe, Masakazu Yamamoto
BMC Gastroenterology.2022;[Epub] CrossRef
Development and validation of a prognostic nomogram for gallbladder cancer patients after surgery
Xinsen Xu, Min He, Hui Wang, Ming Zhan, Linhua Yang
BMC Gastroenterology.2022;[Epub] CrossRef
Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer
Kaushik Neogi, Mallika Tewari, Ashish Kumar Singh, Kavyanjali Sharma, Gullanki Naga Venkata Charan Tej, Sumit Singh Verma, Subash Chandra Gupta, Prasanta Kumar Nayak
Journal of Cancer Research and Therapeutics.2022; 18(3): 668. CrossRef
Postsurgical radiotherapy in stage IIIB gallbladder cancer patients with one to three lymph nodes metastases: A propensity score matching analysis
Yu-Long Cai, Yi-Xin Lin, Xian-Ze Xiong, Hui Ye, Fu-Yu Li, Nan-Sheng Cheng
The American Journal of Surgery.2021; 221(3): 642. CrossRef
S100P as a marker for poor survival and advanced stage in gallbladder carcinoma
Alka Mary Mathai, Jacob Alexander, Hsuan-Ying Huang, Chien-Feng Li, Yung-Ming Jeng, Kar-Ming Fung, William P. Harris, Paul E. Swanson, Camtu Truong, Matthew M. Yeh
Annals of Diagnostic Pathology.2021; 52: 151736. CrossRef
The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update
Xiaoyan Liao, Dongwei Zhang
Archives of Pathology & Laboratory Medicine.2021; 145(5): 543. CrossRef
Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
You-Na Sung, Sung Joo Kim, Sun-Young Jun, Changhoon Yoo, Kyu-Pyo Kim, Jae Hoon Lee, Dae Wook Hwang, Shin Hwang, Sang Soo Lee, Seung-Mo Hong
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis
Hyun Kang, Yoo Shin Choi, Suk-Won Suh, Geunjoo Choi, Jae Hyuk Do, Hyoung-Chul Oh, Hong Jin Kim, Seung Eun Lee
Journal of Clinical Medicine.2021; 10(15): 3317. CrossRef
A Clinical-Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Gallbladder Cancer
Xingyu Liu, Xiaoyuan Liang, Lingxiang Ruan, Sheng Yan
Frontiers in Oncology.2021;[Epub] CrossRef
Manejo endoscópico de adenocarcinoma de vesícula biliar. Presentación de caso
Cristina Fernández-González de la Vega, Víctor Hugo Hernández-Lozada
Revista Mexicana de Cirugía Endoscópica.2021; 22(1): 28. CrossRef

9,545 View
212 Download
32 Web of Science
30 Crossref

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer: Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Sardar Alam, Eleni D. Lagoudaki, Ippokratis Messaritakis, Odysseas Zoras, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos; Cancer Res Treat. 2019;51(4):1518-1526. Published online March 20, 2019; DOI: https://doi.org/10.4143/crt.2019.008

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the prognostic significance of liver kinase b1 (LKB1) loss in patients with operable colon cancer (CC).
Materials and Methods
Two hundred sixty-two specimens from consecutive patients with stage III or high-risk stage II CC, who underwent surgical resection with curative intent and received adjuvant chemotherapy with fluoropyrimidine and oxaliplatin, were analyzed for LKB1 protein expression loss, by immunohistochemistry as well as for KRAS exon 2 and BRAFV600E mutations by Sanger sequencing and TS, ERCC1, MYC, and NEDD9 mRNA expression by real-time quantitative reverse transcription polymerase chain reaction.
Results
LKB1 expression loss was observed in 117 patients (44.7%) patients and correlated with right-sided located primaries (p=0.032), and pericolic lymph nodes involvement (p=0.003), BRAFV600E mutations (p=0.024), and TS mRNA expression (p=0.041). Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors. Multivariate analysis revealed LKB1 expression loss as independent prognostic factor for both decreased DFS (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) and decreased OS (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019).
Conclusion
Loss of tumoral LKB1 protein expression, constitutes an adverse prognostic factor in patients with operable CC.

Citations

Citations to this article as recorded by

Cafestol inhibits colon cancer cell proliferation and tumor growth in xenograft mice by activating LKB1/AMPK/ULK1-dependent autophagy
Yuemei Feng, JiZhuo Yang, Yihan Wang, Xue Wang, Qian Ma, Yalin Li, Xuehui Zhang, Songmei Wang, Qiao Zhang, Fei Mi, Yanjiao Wang, Dubo Zhong, Jianzhong Yin
The Journal of Nutritional Biochemistry.2024; 129: 109623. CrossRef
The Prognostic Significance of NEDD9 Expression in Human Cancers: A Systematic Review, Meta-Analysis, and Omics Exploration
Jehad A. Yasin, Ramez M. Odat, Fares A. Qtaishat, Mohammad-Amer A. Tamimi, Muaath I. Alsufi, Osama M. Younis, Leen A. Alkuttob, Anwaar Saeed
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Phe354Leu polymorphism of the liver kinase B1 gene as a prognostic factor in adult egyptian patients with acute myeloid leukemia
Ola A. Hussein, Hany A. Labib, Rasha Haggag, Maha Mahmoud Hamed Sakr
Heliyon.2023; 9(5): e15415. CrossRef
Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study
Ippokratis Messaritakis, Eleni Psaroudaki, Konstantinos Vogiatzoglou, Maria Sfakianaki, Pantelis Topalis, Ioannis Iliopoulos, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, Maria Tzardi, John Souglakos
Cancers.2023; 15(19): 4819. CrossRef
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Asimina Koulouridi, Michaela Karagianni, Ippokratis Messaritakis, Maria Sfakianaki, Alexandra Voutsina, Maria Trypaki, Maria Bachlitzanaki, Evangelos Koustas, Michalis V. Karamouzis, Anastasios Ntavatzikos, Anna Koumarianou, Nikolaos Androulakis, Dimitrio
Cancers.2022; 14(14): 3320. CrossRef
Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients
Ippokratis Messaritakis, Asimina Koulouridi, Eleni Boukla, Maria Sfakianaki, Konstantinos Vogiatzoglou, Michaela Karagianni, Nikolaos Gouvas, John Tsiaoussis, Evangelos Xynos, Elias Athanasakis, Dimitrios Mavroudis, Maria Tzardi, John Souglakos
Cancers.2022; 14(18): 4407. CrossRef
Peutz-Jeghers syndrome: what has been known for 125 years of research? (review)
Tatiana A. Savelyeva, D. Yu. Pikunov, A. M. Kuzminov, A. S. Tsukanov
Koloproktologia.2021; 20(2): 85. CrossRef
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou, Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, John Souglakos
Cancers.2020; 12(8): 2058. CrossRef
LKB1 inactivation leads to centromere defects and genome instability via p53-dependent upregulation of survivin
Li-Yan Jin, Kui Zhao, Long-Jiang Xu, Rui-Xun Zhao, Kaitlin D. Werle, Yong Wang, Xiao-Long Liu, Qiu Chen, Zhuo-Jun Wu, Ke Zhang, Ying Zhao, Guo-Qin Jiang, Feng-Mei Cui, Zhi-Xiang Xu
Aging.2020; 12(14): 14341. CrossRef
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review
Emma C. Hulshof, Lifani Lim, Ignace H. J. T. de Hingh, Hans Gelderblom, Henk-Jan Guchelaar, Maarten J. Deenen
Frontiers in Pharmacology.2020;[Epub] CrossRef

6,969 View
184 Download
9 Web of Science
10 Crossref

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy: Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(2):493-501. Published online June 18, 2018; DOI: https://doi.org/10.4143/crt.2018.125

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).
Materials and Methods
From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status.
Results
Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFR mutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression.
Conclusion
EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.

Citations

Citations to this article as recorded by

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
Lung Cancer.2024; 187: 107414. CrossRef
Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
Huan-Wei Liang, Yang Liu, Xin-Bin Pan
Aging.2024;[Epub] CrossRef
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura,
Cancer Science.2024; 115(4): 1273. CrossRef
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anast
Journal of Thoracic Oncology.2024; 19(6): 928. CrossRef
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
David J. Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
Current Oncology.2024; 31(3): 1600. CrossRef
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduard
New England Journal of Medicine.2024; 391(7): 585. CrossRef
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
S. Lu, M.-J. Ahn, T. Reungwetwattana, M. Özgüroğlu, T. Kato, J.C.-H. Yang, M. Huang, F. Fujiki, T. Inoue, L.-V. Quang, V. Sriuranpong, D. Vicente, C. Fuentes, A.A. Chaudhry, L. Poole, E. Armenteros Monterroso, Y. Rukazenkov, T. van der Gronde, S.S. Ramali
Annals of Oncology.2024; 35(12): 1116. CrossRef
Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
Chinese Medical Journal.2024;[Epub] CrossRef
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy
Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-we Kim, Hyeong-ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee
Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4243. CrossRef
Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study
Nan Bi, Kunpeng Xu, Hong Ge, Ming Chen, Mingyan E, Li Zhang, Jianzhong Cao, Xu Zhang, Xiao Ding, Bing Xia, Lujun Zhao, Lijie Han, Jiancheng Li, Chen Hu, Luhua Wang
Journal of the National Cancer Center.2023; 3(1): 65. CrossRef
Locally Advanced Lung Cancer
Sarah Oh, George N. Botros, Milan Patel, Missak Haigentz, Eshan Patel, Iaonnis Kontopidis, John Langenfeld, Matthew P. Deek, Salma K. Jabbour
Hematology/Oncology Clinics of North America.2023; 37(3): 533. CrossRef
Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji
Thoracic Cancer.2023; 14(15): 1355. CrossRef
EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Research and Treatment.2023; 55(2): 498. CrossRef
Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
Yang Liu, Huan-Wei Liang, Xin-Bin Pan
Aging.2023;[Epub] CrossRef
Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
Thoracic Cancer.2022; 13(2): 182. CrossRef
Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
Cancer Science.2022; 113(1): 205. CrossRef
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
Po-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, Te-Chun Hsia, Meng-Chih Lin, Min-Hsi Lin, Jin-Yuan Shih, Cheng-Ta Yang, Sheng-Hsiung Yang, Yuh-Min Chen
JTO Clinical and Research Reports.2022; 3(3): 100292. CrossRef
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
Yuxiang Wang, Wenjuan Yu, Jian Shi, Rong Qiu, Nan Jiang, Zhuofan Wang, Jie Yang, Zhongfei Jia, Meng Song
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
Frontiers in Oncology.2022;[Epub] CrossRef
The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion
Yoonki Hong, Sunmin Park, Myoung Kyu Lee
Scientific Reports.2022;[Epub] CrossRef
First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
Meditsinskiy sovet = Medical Council.2022; (22): 12. CrossRef
Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang
Thoracic Cancer.2021; 12(6): 814. CrossRef
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Hea
Journal of Thoracic Oncology.2021; 16(6): 1030. CrossRef
Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren
Mazen A. Juratli, Benjamin Struecker, Shadi Katou, M. Haluk Morguel, Andreas Pascher
Der Chirurg.2021; 92(11): 1003. CrossRef
Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Sonam Puri, Andreas Saltos, Bradford Perez, Xiuning Le, Jhanelle E. Gray
Current Oncology Reports.2020;[Epub] CrossRef
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
Lung Cancer.2020; 146: 23. CrossRef
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
Connor O’Leary, Harry Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Ken J. O’Byrne
Pharmaceuticals.2020; 13(10): 273. CrossRef
MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
Noor Altaleb
Clinical Cancer Drugs.2020; 7(2): 65. CrossRef
Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn, Hojoong Kim
Lung Cancer.2019; 129: 28. CrossRef
A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm
Wang-Yu Zhu, Ke-xin Fang, Jian-ying He, Ri Cui, Yong-Kui Zhang, Han-bo Le
Disease Markers.2019; 2019: 1. CrossRef

13,052 View
469 Download
28 Web of Science
30 Crossref

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial: Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(1):1-11. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2018.028

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m² /day on days 1-14 plus docetaxel 35 mg/m² on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m² /day on days 1-14 plus cisplatin 60 mg/m² on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Citations

Citations to this article as recorded by

Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
International Journal of Hyperthermia.2022; 39(1): 239. CrossRef
Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
Qiang Hu, Yuanshui Sun
Clinical Nutrition.2021; 40(3): 1438. CrossRef
THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
Siberian journal of oncology.2021; 20(1): 133. CrossRef
Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
BMC Cancer.2021;[Epub] CrossRef
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
Cancers.2020; 12(7): 1749. CrossRef
A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
Medicine.2019; 98(7): e14478. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Cutting-edge evidence of adjuvant treatments for gastric cancer
Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109. CrossRef

13,116 View
591 Download
23 Web of Science
11 Crossref

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib: Jeong-Ju Yoo, Goh Eun Chung, Jeong-Hoon Lee, Joon Yeul Nam, Young Chang, Jeong Min Lee, Dong Ho Lee, Hwi Young Kim, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Seoul Liver Group; Cancer Res Treat. 2018;50(2):366-373. Published online May 15, 2017; DOI: https://doi.org/10.4143/crt.2017.126

Abstract PDF PubReader ePub

Purpose
Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status. The aim of this study was to establish a prognostic scoring system and to propose a sub-classification of the Barcelona-Clinic Liver Cancer (BCLC) stage C.
Materials and Methods
This retrospective study included consecutive patientswho received sorafenib for BCLC stage C HCC at a single tertiary hospital in Korea. A Cox proportional hazard model was used to develop a scoring system, and internal validationwas performed by a 5-fold cross-validation. The performance of the model in predicting risk was assessed by the area under the curve and the Hosmer-Lemeshow test.
Results
A total of 612 BCLC stage C HCC patients were sub- classified into strata depending on their performance status. Five independent prognostic factors (Child-Pugh score, α-fetoprotein, tumor type, extrahepatic metastasis, and portal vein invasion) were identified and used in the prognostic scoring system. This scoring system showed good discrimination (area under the receiver operating characteristic curve, 0.734 to 0.818) and calibration functions (both p < 0.05 by the Hosmer-Lemeshow test at 1 month and 12 months, respectively). The differences in survival among the different risk groups classified by the total score were significant (p < 0.001 by the log-rank test in both the Eastern Cooperative Oncology Group 0 and 1 strata).
Conclusion
The heterogeneity of patientswith BCLC stage C HCC requires sub-classification of advanced HCC. A prognostic scoring system with five independent factors is useful in predicting the survival of patients with BCLC stage C HCC.

Citations

Citations to this article as recorded by

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
Frontiers in Oncology.2024;[Epub] CrossRef
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon,
Clinical Cancer Research.2024; 30(13): 2812. CrossRef
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Development and validation of web‐based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database
Guizhong Huang, Qiaohong Lin, Pengfei Yin, Kai Mao, Jianlong Zhang
Cancer Medicine.2023; 12(12): 13167. CrossRef
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Li, Jinglong Chen
The Oncologist.2023; 28(10): e942. CrossRef
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
Li Li, Xiaomi Li, Wendong Li, Xiaoyan Ding, Yongchao Zhang, Jinglong Chen, Wei Li
BMC Cancer.2022;[Epub] CrossRef
Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma
Min Chen, Guang-Bo Wu, Shan Hua, Zhi-Feng Zhao, Hong-Jie Li, Meng Luo
Frontiers in Genetics.2022;[Epub] CrossRef
Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
Jian-Xu Li, Mei-Ling He, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Jian-Hong Zhong, Rui-Jun Zhang, Chun-Feng Liang, Ya-Dan Pang, Jun-Kun He, Qian-Qian Chen, Jin-Xia Weng, Shi-Xiong Liang, Bang-De Xiang
BMC Gastroenterology.2022;[Epub] CrossRef
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marc
Cancers.2021; 13(11): 2677. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub] CrossRef
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef
Liver International.2020; 40(1): 215. CrossRef
A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Tingting Zhang, Zhe Liu, Xiangqian Zhao, Zhiyuan Mao, Li Bai
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2246. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
Bo Hyun Kim, Joong-Won Park
Journal of Korean Medical Science.2018;[Epub] CrossRef

9,446 View
307 Download
18 Web of Science
16 Crossref

Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model: Hyo Joon Jang, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Hee Chul Yang, Dong Kwan Kim; Cancer Res Treat. 2017;49(4):898-905. Published online January 18, 2017; DOI: https://doi.org/10.4143/crt.2016.312

Abstract PDF PubReader ePub

Purpose
We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model.
Materials and Methods
Patientswho underwent curative resection for stage IB lung adenocarcinomawere analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence-free survival and overall survival were compared between these two groups.
Results
A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019).
Conclusion
Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.

Citations

Citations to this article as recorded by

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
Zi-Qing Shen, Kun-Peng Feng, Zi-Yao Fang, Tian Xia, Shu Pan, Cheng Ding, Chun Xu, Sheng Ju, Jun Chen, Chang Li, Jun Zhao
Journal of Cardiothoracic Surgery.2024;[Epub] CrossRef
Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, Juliana Guarize, Antonio Passaro, Filippo De Marinis, Patrick Maisonneuve, Lorenzo Spaggiari
Journal of Clinical Medicine.2023; 12(5): 2081. CrossRef
A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
Xue Song, Yangyang Xie, Haoran Deng, Fei Yu, Shiqiang Wang, Yafang Lou
Cancer Control.2023;[Epub] CrossRef
Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
Ke Zhou, Yaqin Zhao, Linchuan Liang, Jie Cao, Huahang Lin, Zhiyu Peng, Jiandong Mei
Frontiers in Oncology.2022;[Epub] CrossRef
A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer
Wei Wang, Fei Teng, Shi Bu, Wei Xu, Qing-Chun Cai, Yue-Quan Jiang, Zhi-Qiang Wang
Risk Management and Healthcare Policy.2022; Volume 15: 1581. CrossRef
Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
Matvey M. Tsyganov, Evgeny O. Rodionov, Marina K. Ibragimova, Sergey V. Miller, Olga V. Cheremisina, Irina G. Frolova, Sergey A. Tuzikov, Nikolai V. Litviakov
Journal of Personalized Medicine.2022; 12(10): 1647. CrossRef
Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort
Zhichao Zuo, Guochao Zhang, Peng Song, Jing Yang, Shuiting Li, Zhi Zhong, Qinghao Tan, Liming Wang, Qi Xue, Shugeng Gao, Nan Sun, Jie He
Annals of Surgical Oncology.2021; 28(7): 3941. CrossRef
Drug Regimen for Patients after a Pneumonectomy
Noheul Kim, Ronny Priefer
Journal of Respiration.2021; 1(2): 114. CrossRef
Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level
Khashchuluun Batmunkh, Sukki Cho, Sungwon Yum, Kwhanmien Kim, Sanghoon Jheon
Interactive CardioVascular and Thoracic Surgery.2020; 30(6): 820. CrossRef
Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion
Jun Xie, Xian Zhang, Song Hu, Wan-Da Peng, Bin Xu, Yan Li, Su-Juan Zhang, Qing Li, Chong Li
Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2231. CrossRef

8,506 View
187 Download
12 Web of Science
10 Crossref

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer: Jae Myoung Noh, Yong Chan Ahn, Hyebin Lee, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Hyojung Park, Eonju Lee, Keunchil Park, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun; Cancer Res Treat. 2015;47(4):645-652. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.144

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate the treatment outcomes following definitive bimodality concurrent chemoradiotherapy (CCRT) in patients with inoperable N2-positive stage IIIA (N2- IIIA) non-small cell lung cancer (NSCLC). Materials and Methods From May 1997 to December 2012, 65 out of 633 patients with N2-IIIA NSCLC received bimodality therapy. The treatment modality was selected during/after neoadjuvant CCRT in 21 patients or primarily at diagnosis in 44 through a multidisciplinary consensus meeting. The median age was 65 years (range, 36 to 76 years). Sixty patients (92.3%) had clinically evident N2 disease, while 22 (33.8%) had multi-station N2 involvement. The median radiation therapy dose was 66 Gy in 33 fractions, while the dose was elevated to 72 Gy in 13 patients who had a treatment break due to delayed decision regarding resectability. The most frequent chemotherapy regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin (54, 83.1%).
Results
During the median follow-up of 18.8 months (range, 1.6 to 173.1 months), 34 patients (52.3%) experienced disease progression, with distant metastasis being the most common first treatment failure pattern (23, 34.8%). The median and 2-year rates of progression-free survival were 18.8 months and 45.9%, respectively. The median and 2-year rates of overall survival were 28.6 months and 50.1%, respectively. Conclusion Definitive bimodality therapy in patients with N2-IIIA NSCLC demonstrated favorable outcomes, while trimodality therapy could be considered for candidates for less than pneumonectomy.

Citations

Citations to this article as recorded by

Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
Life.2022; 12(2): 292. CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
Radiation Oncology Journal.2021; 39(1): 24. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer
Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung, Mei-Fang Wang
Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1441. CrossRef
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
The Oncologist.2019; 24(2): 157. CrossRef
Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
Lung Cancer.2018; 115: 89. CrossRef

13,777 View
89 Download
5 Web of Science
6 Crossref

Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy: Jae Myoung Noh, Jin Man Kim, Yong Chan Ahn, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Sang Gyu Ju, Jin Sung Kim, Jung Suk Shin, Chae-Seon Hong, Hyojung Park, Eonju Lee; Cancer Res Treat. 2016;48(1):106-114. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.131

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate clinical outcomes following definitive concurrent chemoradiotherapy (CCRT) for patients with N3-positive stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC), with a focus on radiation therapy (RT) techniques. Materials and Methods From May 2010 to November 2012, 77 patients with N3-IIIB NSCLC received definitive CCRT (median, 66 Gy). RT techniques were selected individually based on estimated lung toxicity, with 3-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) delivered to 48 (62.3%) and 29 (37.7%) patients, respectively. Weekly docetaxel/paclitaxel plus cisplatin (67, 87.0%) was the most common concurrent chemotherapy regimen.
Results
The median age and clinical target volume (CTV) were 60 years and 288.0 cm3, respectively. Patients receiving IMRT had greater disease extent in terms of supraclavicular lymph node (SCN) involvement and CTV ≥ 300 cm3. The median follow-up time was 21.7 months. Fortyfive patients (58.4%) experienced disease progression, most frequently distant metastasis (39, 50.6%). In-field locoregional control, progression-free survival (PFS), and overall survival (OS) rates at 2 years were 87.9%, 38.7%, and 75.2%, respectively. Although locoregional control was similar between RT techniques, patients receiving IMRT had worse PFS and OS, and SCN metastases from the lower lobe primary tumor and CTV ≥ 300 cm3were associated with worse OS. The incidence and severity of toxicities did not differ significantly between RT techniques. Conclusion IMRT could lead to similar locoregional control and toxicity, while encompassing a greater disease extent than 3D-CRT. The decision to apply IMRT should be made carefully after considering oncologic outcomes associated with greater disease extent and cost.

Citations

Citations to this article as recorded by

Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen, He Wang, Jun Dang
International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1179. CrossRef
“Mid-P strategy” versus “internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P
Line Claude, Camille Schiffler, Vanina Isnardi, Séverine Metzger, Sophie Darnis, Isabelle Martel-Lafay, Thomas Baudier, Simon Rit, David Sarrut, Myriam Ayadi
Radiotherapy and Oncology.2024; 199: 110435. CrossRef
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Tingting Liu, Sihan Li, Silu Ding, Jingping Qiu, Chengbo Ren, Jun Chen, He Wang, Xiaoling Wang, Guang Li, Zheng He, Jun Dang
eClinicalMedicine.2023; 64: 102246. CrossRef
The effect of radiotherapy and surgery on stage IIIA/B NSCLC patients treated with chemotherapy
Y. Zeng, G. Wang, H. Zheng, Y. Wang, G. Ma, Z. Pang, J. Du
International Journal of Radiation Research.2023; 21(3): 475. CrossRef
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
Life.2022; 12(2): 292. CrossRef
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients
Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim
Medicina.2021; 57(3): 301. CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
Radiation Oncology Journal.2021; 39(1): 24. CrossRef
Comparaison dosimétrique et de la toxicité de la radiothérapie conformationnelle avec modulation d’intensité et de la radiothérapie conformationnelle tridimensionnelle des carcinomes bronchiques non à petites cellules
F. Guillemin, L. Berger, M. Lapeyre, A. Bellière-Calandry
Cancer/Radiothérapie.2021; 25(8): 747. CrossRef
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
Lung Cancer.2020; 146: 23. CrossRef
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Rocco Giannicola, Graziella D'Arrigo, Cirino Botta, Rita Agostino, Pietro Del Medico, Antonia Falzea, Vito Barbieri, Nicoletta Staropoli, Teresa Del Giudice, Pierpaolo Pastina, Valerio Nardone, Marika Monoriti, Graziella Calabrese, Giovanni
Molecular and Clinical Oncology.2019;[Epub] CrossRef
Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
Min Wei, Qingqing Ye, Xuan Wang, Men Wang, Yan Hu, Yonghua Yang, Jiyuan Yang, Jun Cai
Medicine.2018; 97(19): e0632. CrossRef
Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer
John Boyle, Brad Ackerson, Lin Gu, Chris R. Kelsey
Advances in Radiation Oncology.2017; 2(1): 6. CrossRef
Normal lung sparing Tomotherapy technique in stage III lung cancer
Chae-Seon Hong, Sang Gyu Ju, Yong Chan Ahn, Gyu Sang Yoo, Jae Myoung Noh, Dongryul Oh, Kwangzoo Chung, Hongryull Pyo, Kwanghyun Jo
Radiation Oncology.2017;[Epub] CrossRef
Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry
Pierre Truntzer, Delphine Antoni, Nicola Santelmo, Catherine Schumacher, Pierre-Emmanuel Falcoz, Elisabeth Quoix, Gilbert Massard, Georges Noël
Reports of Practical Oncology & Radiotherapy.2016; 21(5): 427. CrossRef
Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer
Minal S. Kale, Grace Mhango, Marcelo Bonomi, Alex Federman, Keith Sigel, Kenneth E. Rosenzweig, Juan P. Wisnivesky
Annals of the American Thoracic Society.2016; 13(9): 1593. CrossRef

19,018 View
155 Download
20 Web of Science
16 Crossref

Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study: Kyu-Won Jung, Young-Joo Won, Hyun-Joo Kong, Chang-Mo Oh, Aesun Shin, Jin-Soo Lee; Cancer Res Treat. 2013;45(3):162-171. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.162

Abstract PDF PubReader ePub

PURPOSE
Although the cancer stage at diagnosis is the most important prognostic factor for patients' survival, there are few population-based estimates of stage-specific survival outcome, especially in Asian countries. Our study aims to estimate stage-specific survival for Korean patients.
MATERIALS AND METHODS
We analyzed the Korea National Cancer Incidence Database data on 626,506 adult patients aged > or = 20 years, who were diagnosed between 2006 and 2010 with stomach, colorectal, liver, lung, breast, cervix, prostate, and thyroid cancers. Patients were followed up to December 2011, and the 5-year relative survival rates (RSRs) were calculated for gender and age group by Surveillance, Epidemiology, and End Results (SEER) stage at diagnosis.
RESULTS
The 5-year RSRs for all localized-stage cancers, except for lung and liver, exceeded 90% with that for thyroid cancer being the highest at 100.4%. These values for distant stage liver, lung, and stomach cancers were very dismal at 2.5%, 4.8%, and 5.5%, respectively, while it was 69.1% for thyroid cancer, and was in the range of 18.3-36.4% for colorectal, cervix, breast and prostate cancers. Overall, the 5-year RSRs for all cancer types decreased with aging across all the disease stages with exception of prostate cancer, which suggests biologic difference in these cancer types in a young age group. When compared with US SEER data, Korean patients had better stage-specific survival rates for stomach, colorectal, liver, and cervical cancers.
CONCLUSION
Korean cancer patients showed relatively favorable stage distribution and 5-year RSRs, which suggests potential contribution of the national cancer screening program.

Citations

Citations to this article as recorded by

Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer
Donghyun Lee, Bumjin Lim, Tuan Thanh Nguyen, Se Young Choi
Journal of Personalized Medicine.2024; 14(5): 517. CrossRef
Clinical outcomes of argon plasma coagulation for the treatment of gastric low-grade dysplasia
Hoyoung Wang, Ji Yong Ahn, Jin Hee Noh, Hee Kyoung Na, Kee Wook Jung, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
Gastrointestinal Endoscopy.2024; 100(2): 221. CrossRef
Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort
Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang
Cancers.2024; 16(13): 2291. CrossRef
Impact of Disability Status on Mortality in Patients with Gastric Cancer: A Nationwide Study Focusing on Regional Disparities
Woo-Ri Lee, Kyu-Tae Han, Mingee Choi, Seojin Park, Woorim Kim
Healthcare.2023; 11(5): 641. CrossRef
Examining Final-Administered Medication as a Measure of Data Quality: A Comparative Analysis of Death Data with the Central Cancer Registry in Republic of Korea
Yae Won Tak, Jeong Hyun Han, Yu Jin Park, Do-Hoon Kim, Ji Seon Oh, Yura Lee
Cancers.2023; 15(13): 3371. CrossRef
Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer
Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
Cancers.2023; 15(16): 4114. CrossRef
Trends of stomach cancer survival: A systematic review of survival rates from population‐based cancer registration
Jia Yi Tuo, Jing Hao Bi, Hui Yun Yuan, Yu Fei Jiang, Xiao Wei Ji, Hong Lan Li, Yong Bing Xiang
Journal of Digestive Diseases.2022; 23(1): 22. CrossRef
Risk of Psoriasis in Postgastrectomy Gastric Cancer Survivors: A Nationwide Population-Based Cohort Study
Bo Ri Kim, Dong Ho Lee, Hyun Ik Shim, Jee Woo Kim, Sanghyun Park, Cheol Min Shin, Kyungdo Han, Sang Woong Youn
Annals of Dermatology.2022; 34(3): 191. CrossRef
A novel ferroptosis-related long noncoding RNA signature for relapse free survival prediction in patients with breast cancer
Yuzhi Wang, Yunfei Xu, Yi Zhang
Medicine.2022; 101(31): e29573. CrossRef
Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review
Sophie Pilleron, Helen Gower, Maryska Janssen-Heijnen, Virginia Claire Signal, Jason K Gurney, Eva JA Morris, Ruth Cunningham, Diana Sarfati
BMJ Open.2021; 11(3): e044239. CrossRef
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?
Chang‐Mo Oh, Jiwon Lim, Yuh Seog Jung, Yeol Kim, Kyu‐Won Jung, Seri Hong, Young‐Joo Won
Cancer Medicine.2021; 10(12): 4087. CrossRef
Net survival differences of breast cancer between stages at diagnosis and age groups in the east coast region of West Malaysia: a retrospective cohort study
Tengku Muhammad Hanis, Najib Majdi Yaacob, Suhaily Mohd Hairon, Sarimah Abdullah
BMJ Open.2021; 11(5): e043642. CrossRef
Improving the Early Diagnosis of Gastric Cancer
Robert J. Huang, Joo Ha Hwang
Gastrointestinal Endoscopy Clinics of North America.2021; 31(3): 503. CrossRef
Effect of Pap smear screening on cervical cancer stage at diagnosis: results from the Korean National Cancer Screening Program
Cam Nhung Bui, Seri Hong, Mina Suh, Jae Kwan Jun, Kyu Won Jung, Myong Cheol Lim, Kui Son Choi
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Bacteria-Derived Extracellular Vesicles in Urine as a Novel Biomarker for Gastric Cancer: Integration of Liquid Biopsy and Metagenome Analysis
Jae-Yong Park, Chil-Sung Kang, Ho-Chan Seo, Jin-Chul Shin, Sung-Min Kym, Young-Soo Park, Tae-Seop Shin, Jae-Gyu Kim, Yoon-Keun Kim
Cancers.2021; 13(18): 4687. CrossRef
The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis
Yanlong Shi, Wei Wei, Li Li, Qian Wei, Fei Jiang, Guozhi Xia, Hongzhu Yu
Bioengineered.2021; 12(2): 12246. CrossRef
Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis
Xiaojian Qin, Dingwei Ye, Chengyuan Gu, Yongqiang Huang, Weijie Gu, Bo Dai, Hailiang Zhang, Yao Zhu, Han Yang, Shuli Qu
Current Therapeutic Research.2021; 95: 100653. CrossRef
CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer
Xu Chang, Peng Sun, Jianxin Zhang, Lin Zhang, Huiyong Wu, Yinfa Xie, Jibing Liu
Medicine.2021; 100(52): e28407. CrossRef
Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis
Meiling Xiao, Bicong Yan, Ying Li, Jingjing Lu, Jinwei Qiang
European Radiology.2020; 30(3): 1405. CrossRef
Burden of male hardcore smokers and its characteristics among those eligible for lung cancer screening
Dong Won Park, Ji-Yun Jang, Tai Sun Park, Hyun Lee, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Ho Joo Yoon, Dae Ryong Kang, Jang Won Sohn
BMC Public Health.2020;[Epub] CrossRef
Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4
Dong Ha Kim, Sojung Park, HyeongRyul Kim, Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Young Hoon Sung, Chang-Min Choi, Miyong Yun, Young-Su Yi, Chae Won Lee, Sang-Yeob Kim, Jae Cheol Lee, Jin Kyung Rho
Cancer Letters.2020; 475: 2. CrossRef
A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea
Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn
Journal of Liver Cancer.2020; 20(1): 53. CrossRef
Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer
Yang Li, Hong‐Chang Wang, Jin‐Shen Wang, Bo Sun, Le‐Ping Li
FEBS Open Bio.2020; 10(6): 1149. CrossRef
The Management of Gastric Intestinal Metaplasia in the United States: A Controversial Topic
Robert J. Huang, Joo Ha Hwang
Gastroenterology.2020; 159(1): 402. CrossRef
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
Cancer Research and Treatment.2020; 52(3): 661. CrossRef
Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer
Jun-Xian Du, Cong Chen, Yi-Hong Luo, Jia-Liang Cai, Cheng-Zhe Cai, Jing Xu, Xiao-Jian Ni, Wei Zhu
Gene.2020; 762: 144974. CrossRef
The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis
H.J. Oh, B.-H. Yoon, Y.-C. Ha, D.-C. Suh, S.-M. Lee, K.-H. Koo, Y.-K. Lee
Osteoporosis International.2020; 31(2): 267. CrossRef
Aggressive Local Treatment Improves Survival in Stage IV Breast Cancer With Synchronous Metastasis
Chen-Lu Lian, Li-Yi Guo, Lei Zhang, Jun Wang, Jian Lei, Li Hua, Zhen-Yu He, San-Gang Wu
Frontiers in Oncology.2020;[Epub] CrossRef
Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer
Yang Li, Jin-Shen Wang, Yun Guo, Tao Zhang, Le-Ping Li
World Journal of Gastroenterology.2020; 26(44): 6963. CrossRef
One Size Does Not Fit All: Marked Heterogeneity in Incidence of and Survival from Gastric Cancer among Asian American Subgroups
Robert J. Huang, Nora Sharp, Ruth O. Talamoa, Hanlee P. Ji, Joo Ha Hwang, Latha P. Palaniappan
Cancer Epidemiology, Biomarkers & Prevention.2020; 29(5): 903. CrossRef
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(1): 1. CrossRef
Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification
Se Young Choi, Jeman Ryu, Dalsan You, Jun Hyuk Hong, Hanjong Ahn, Choung‐Soo Kim
International Journal of Urology.2019; 26(1): 62. CrossRef
A Chance to Cut Is a Chance to Cure: Endoscopic Submucosal Dissection for Early Gastric Cancer
Robert J. Huang, Gregory W. Charville, Joo Ha Hwang, Shai Friedland
Digestive Diseases and Sciences.2019; 64(5): 1129. CrossRef
Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population
Su-Min Jeong, Dong Wook Shin, Ji Eun Lee, Sang-Man Jin, Sung Kim
Cancer Research and Treatment.2019; 51(2): 530. CrossRef
Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea
Young-Tak Kim, Beatriz Serrano, Jae-Kwan Lee, Hyunju Lee, Shin-Wha Lee, Crystal Freeman, Jin-Kyoung Oh, Laia Alemany, Francesc-Xavier Bosch, Laia Bruni
Papillomavirus Research.2019; 7: 26. CrossRef
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
Cancer Research and Treatment.2019; 51(2): 819. CrossRef
Comparative Effectiveness of Abdominal versus Laparoscopic Radical Hysterectomy for Cervical Cancer in the Postdissemination Era
Jin Hee Kim, Kyungjoo Kim, Seo Jin Park, Jung-Yun Lee, Kidong Kim, Myong Cheol Lim, Jae Weon Kim
Cancer Research and Treatment.2019; 51(2): 788. CrossRef
Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients
Canchang Cheng, Qicai Wang, Minggu Zhu, Kelong Liu, Zhiqiao Zhang
Cancer Cell International.2019;[Epub] CrossRef
Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics
Chaewon Shin, Han-Kwang Yang, SungHye Park, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Yeon-Ju Huh, Yun-Jeong Kim, So-Yong Park, Tae-Beom Ahn, Seok Hwa Lee, Han-Joon Kim, Beomseok Jeon
Journal of Clinical Neuroscience.2019; 66: 26. CrossRef
Risk of Dementia in Gastric Cancer Survivors Who Underwent Gastrectomy: A Nationwide Study in Korea
Yoon Jin Choi, Dong Wook Shin, Wooyoung Jang, Dong Ho Lee, Su-Min Jeong, Sanghyun Park, Kyung-do Han, Yong Gyu Park
Annals of Surgical Oncology.2019; 26(13): 4229. CrossRef
Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Cancer Immunology, Immunotherapy.2019; 68(11): 1779. CrossRef
Increased Risk of Osteoporotic Fracture in Postgastrectomy Gastric Cancer Survivors Compared With Matched Controls: A Nationwide Cohort Study in Korea
Dong Wook Shin, Beomseok Suh, Hyunsun Lim, Yun-Suhk Suh, Yoon Jin Choi, Su-Min Jeong, Jae Moon Yun, Sun Ok Song, Youngmin Park
American Journal of Gastroenterology.2019; 114(11): 1735. CrossRef
Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis
Yang Li, Xiao‑Bo Guo, Jin Wang, Hong‑Chang Wang, Le‑Ping Li
Molecular Medicine Reports.2019;[Epub] CrossRef
Primary Care Comprehensiveness Can Reduce Emergency Department Visits and Hospitalization in People with Hypertension in South Korea
Nak-Jin Sung, Yong-Jun Choi, Jae-Ho Lee
International Journal of Environmental Research and Public Health.2018; 15(2): 272. CrossRef
Liver cirrhosis and cancer: comparison of mortality
Wankyo Chung, Changik Jo, Woo Jin Chung, Dong Joon Kim
Hepatology International.2018; 12(3): 269. CrossRef
Reproduction of Gastric Cancer Prognostic Score by real-time quantitative polymerase chain reaction assay in an independent cohort
Kyoung-Mee Kim, Jeeyun Lee, Se Hoon Park, You Jeong Heo, Ji Ryun Jang, Seungtae Kim, Joon Oh Park, Won Ki Kang, Dakeun Lee, Sang-Uk Han, Ji Young An, Min Gew Choi, Tae Sung Sohn, Jae Moon Bae, Sung Kim
Precision and Future Medicine.2018; 2(1): 27. CrossRef
Long-term survival of patients with thyroid cancer according to the methods of tumor detection: A nationwide cohort study in Korea
Yuh-Seog Jung, Chang-Mo Oh, Yeol Kim, Kyu-Won Jung, Junsun Ryu, Young-Joo Won, Pierlorenzo Pallante
PLOS ONE.2018; 13(4): e0194743. CrossRef
Factors related to cancer screening behaviors
Boyoung Choi, Tae Rim Um, Kwang-Soo Lee
Epidemiology and Health.2018; 40: e2018011. CrossRef
Radiological Report of Pilot Study for the Korean Lung Cancer Screening (K-LUCAS) Project: Feasibility of Implementing Lung Imaging Reporting and Data System
Ji Won Lee, Hyae Young Kim, Jin Mo Goo, Eun Young Kim, Soo Jung Lee, Tae Jung Kim, Yeol Kim, Juntae Lim
Korean Journal of Radiology.2018; 19(4): 803. CrossRef
The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes
Jong-Hun Kim, Mina Ha
Journal of Korean Medical Science.2018;[Epub] CrossRef
Lifestyle interventions to alleviate side effects on prostate cancer patients receiving androgen deprivation therapy: a meta-analysis
Miaofa Ying, Rui Zhao, Deqi Jiang, Shenglong Gu, Mingxing Li
Japanese Journal of Clinical Oncology.2018; 48(9): 827. CrossRef
Dual Energy Spectral CT Imaging in the assessment of Gastric Cancer and cell proliferation: A Preliminary Study
Sai-Ming Cheng, Wei Ling, Jiong Zhu, Jian-Rong Xu, Lian-Ming Wu, Hong-Xia Gong
Scientific Reports.2018;[Epub] CrossRef
Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis
San-Gang Wu, Feng-Yan Li, Yue Chen, Jia-Yuan Sun, Huan-Xin Lin, Qin Lin, Zhen-Yu He
Journal of Cancer Research and Clinical Oncology.2017; 143(3): 467. CrossRef
Thyroid Cancer Overdiagnosis Is a Result of Screening Programs in South Korea
Elizabeth N. Pearce
Clinical Thyroidology.2017; 29(1): 8. CrossRef
Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening
Maru Kim, Hyung-Jin Kim, In Kyu Lee, Seong-Taek Oh, Kyungja Han
European Surgery.2017; 49(3): 127. CrossRef
Supervivencia global de pacientes con cáncer en el Instituto Nacional de Cancerología (INC)
Constanza Pardo, Esther de Vries
Revista Colombiana de Cancerología.2017; 21(1): 12. CrossRef
Predictive and Prognostic Biomarkers of Respiratory Diseases due to Particulate Matter Exposure
Hyo Jeong Kim, Min Gi Choi, Moo Kyun Park, Young Rok Seo
Journal of Cancer Prevention.2017; 22(1): 6. CrossRef
The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis
San-Gang Wu, Hui Li, Li-Ying Tang, Jia-Yuan Sun, Wen-Wen Zhang, Feng-Yan Li, Yong-Xiong Chen, Zhen-Yu He
Tumor Biology.2017; 39(6): 101042831770508. CrossRef
Cancer survival in Qidong between 1972 and 2011: A population-based analysis
Jian-Guo Chen, Jian Zhu, Yong-Hui Zhang, Yi-Xin Zhang, Deng-Fu Yao, Yong-Sheng Chen, Jian-Hua Lu, Lu-Lu Ding, Hai-Zhen Chen, Chao-Yong Zhu, Li-Ping Yang, Yuan-Rong Zhu, Fu-Lin Qiang
Molecular and Clinical Oncology.2017; 6(6): 944. CrossRef
Influence of Socioeconomic Status, Comorbidity, and Disability on Late-stage Cancer Diagnosis
Bo Ram Park, So Young Kim, Dong Wook Shin, Hyung Kook Yang, Jong Hyock Park
Osong Public Health and Research Perspectives.2017; 8(4): 264. CrossRef
Emergency Department Visits Can Be Reduced by Having a Regular Doctor for Adults with Diabetes Mellitus: Secondary Analysis of 2013 Korea Health Panel Data
Clara Lee, Nak-Jin Sung, Hyeong-Seok Lim, Jae-Ho Lee
Journal of Korean Medical Science.2017; 32(12): 1921. CrossRef
Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity
Gyeong Eun Min, Hanjong Ahn
Oncology Letters.2017; 13(6): 4832. CrossRef
The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis
San-Gang Wu, Wen-Weng Zhang, Jia-Yuan Sun, Feng-Yan Li, Huan-Xin Lin, Juan Zhou, Zhen-Yu He
Oncotarget.2017; 8(40): 67851. CrossRef
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
Jiwon Koh, Chan-Young Ock, Jin Won Kim, Soo Kyung Nam, Yoonjin Kwak, Sumi Yun, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Oncotarget.2017; 8(16): 26356. CrossRef
Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese
Eunjung Lee, Lihua Liu, Juanjuan Zhang, Mariana C. Stern, Afsaneh Barzi, Amie Hwang, Andre E. Kim, Ann S. Hamilton, Anna H. Wu, Dennis Deapen
Cancer Epidemiology, Biomarkers & Prevention.2017; 26(4): 587. CrossRef
Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China
Y.H. Che, V. Chongsuvivatwong, L. Li, H. Sriplung, Y.Y. Wang, J. You, S.J. Ma, Y. Yan, R.Y. Zhang, T. Shen, H.M. Chen, S.F. Rao, X.L. Zhang
Public Health.2016; 130: 13. CrossRef
Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer
Keun-Wook Lee, Ju Hyun Lee, Jin Won Kim, Ji-Won Kim, Soyeon Ahn, Jee Hyun Kim
Journal of Cancer Research and Clinical Oncology.2016; 142(3): 687. CrossRef
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
Choong-kun Lee, Minkyu Jung, Inkyung Jung, Su Jin Heo, Yong Hyu Jeong, Ji Yeong An, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung
Annals of Surgery.2016; 263(1): 96. CrossRef
DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer
Mi-Kyung Kim, In-Ho Lee, Ki-Heon Lee, Yoo Kyung Lee, Kyeong A So, Sung Ran Hong, Chang-Sun Hwang, Mee-Kyung Kee, Jee Eun Rhee, Chun Kang, Soo Young Hur, Jong Sup Park, Tae-Jin Kim
Journal of Gynecologic Oncology.2016;[Epub] CrossRef
Metastatic Thyroid Gland Tumor Presenting as an Initial Manifestation of Recurrent Uterine Cervical Cancer
So Dam Hong, Jae Kyoung Shin, Hee Jin Hong, Jin Hyung Heo, So Young Chong, Doyoun Oh, Jisu Oh
The Korean Journal of Medicine.2016; 90(1): 68. CrossRef
Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study
Cadeyrn J. Gaskin, Steve F. Fraser, Patrick J. Owen, Melinda Craike, Liliana Orellana, Patricia M. Livingston
Journal of Cancer Survivorship.2016; 10(6): 972. CrossRef
Aberrant methylation ofPCDH10andRASSF1Agenes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
Charinya Pimson, Tipaya Ekalaksananan, Chamsai Pientong, Supannee Promthet, Nuntiput Putthanachote, Krittika Suwanrungruang, Surapon Wiangnon
PeerJ.2016; 4: e2112. CrossRef
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
Sojung Park, Hyun Jung Kim, Chang–Min Choi, Dae Ho Lee, Sang–We Kim, Jung–Shin Lee, Woo Sung Kim, Se Hoon Choi, Jin Kyung Rho, Jae Cheol Lee
BMC Cancer.2016;[Epub] CrossRef
Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study
Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
Cancer Research and Treatment.2016; 48(3): 899. CrossRef
Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort
Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
Journal of Korean Medical Science.2016; 31(11): 1802. CrossRef
Does the interval of screening endoscopy affect survival in gastric cancer patients?
Jieun Kim, Su Mi Kim, Man Ho Ha, Jeong Eun Seo, Min-Gew Choi, Jun Ho Lee, Tae Sung Sohn, Sung Kim, Sin-Ho Jung, Jae Moon Bae
Medicine.2016; 95(49): e5490. CrossRef
Gastric cancer survival and affiliation to health insurance in a middle-income setting
Esther de Vries, Claudia Uribe, Constanza Pardo, Valery Lemmens, Ellen Van de Poel, David Forman
Cancer Epidemiology.2015; 39(1): 91. CrossRef
Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea
K S Choi, J K Jun, M Suh, B Park, D K Noh, S H Song, K W Jung, H-Y Lee, I J Choi, E-C Park
British Journal of Cancer.2015; 112(3): 608. CrossRef
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
Jin Won Kim, In Sil Choi, Yu Jung Kim, Kyung-Hun Lee, Keun-Wook Lee, Tae-Yong Kim, Sae-Won Han, Jee Hyun Kim, Tae-You Kim, Jong Seok Lee, Yung-Jue Bang, Seock-Ah Im, Do-Youn Oh
Cancer Chemotherapy and Pharmacology.2015; 75(6): 1175. CrossRef
The Korean guideline for lung cancer screening
Seung Hun Jang, Seungsoo Sheen, Hyae Young Kim, Hyeon Woo Yim, Bo Young Park, Jae Woo Kim, In Kyu Park, Young Whan Kim, Kye Young Lee, Kyung Soo Lee, Jong Mog Lee, Bin Hwangbo, Sang Hyun Paik, Jin-Hwan Kim, Nak Jin Sung, Sang-hyun Lee, Seung-sik Hwang, So
Journal of the Korean Medical Association.2015; 58(4): 291. CrossRef
The Korean guideline for gastric cancer screening
Hyun Ah Park, Su Youn Nam, Sang Kil Lee, Sang Gyun Kim, Ki-Nam Shim, Sang Min Park, Sun-Young Lee, Hye Seung Han, Yong Moon Shin, Kyoung-Mee Kim, Kyung-Jae Lee, Tae-Yong Lee, Il Ju Choi, Seong Sook Hong, Jae Woo Kim, Yoon Jae Lee, Soo Young Kim, Yeol Kim,
Journal of the Korean Medical Association.2015; 58(5): 373. CrossRef
The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database
Zisun Kim, Sun Young Min, Chan Seok Yoon, Kyu-Won Jung, Beom Seok Ko, Eunyoung Kang, Seok Jin Nam, Seokwon Lee, Min Hee Hur
Journal of Breast Cancer.2015; 18(2): 103. CrossRef
Management of gastric cancer: East vs west
Sook Ryun Park
Current Problems in Cancer.2015; 39(6): 315. CrossRef
Correlation between Serum 1,25-Dihydroxyvitamin D Levels and Breast Cancer Prognosis in Korea
Hae Won Bang, Seung Taek Lim, Ye Won Jeon, Young Jin Suh
Journal of Breast Disease.2015; 3(2): 37. CrossRef
Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma
Jung-Yun Lee, Young Tae Kim, Sunghoon Kim, Boram Lee, Myong Cheol Lim, Jae-Weon Kim, Young-Joo Won, Jose G. Trevino
PLOS ONE.2015; 10(12): e0144887. CrossRef
Health Behaviors of Breast Cancer Survivors with Hypertension: A Propensity Analysis of KNHANES III-V (2005-2012)
Ju-Ri Jeong, Sun Kim, So-Ra Jo, Ju-Youn Joh, Yeon-Pyo Kim, Yinglin Xia
PLOS ONE.2015; 10(5): e0127346. CrossRef
The Basic Facts of Korean Breast Cancer in 2011: Results of a Nationwide Survey and Breast Cancer Registry Database
Zisun Kim, Sun Young Min, Chan Seok Yoon, Hun Jae Lee, Jung Sun Lee, Hyun Jo Youn, Heung Kyu Park, Dong-Young Noh, Min Hee Hur
Journal of Breast Cancer.2014; 17(2): 99. CrossRef
Preoperative MRI criteria for trials on less radical surgery in Stage IB1 cervical cancer
Jung-Yun Lee, Jina Youm, Tae Hun Kim, Jeong Yeon Cho, Min A Kim, Dong Hoon Suh, Myong Cheol Lim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Gynecologic Oncology.2014; 134(1): 47. CrossRef
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
Hee Kyung Ahn, Minkyu Jung, Sun Jin Sym, Dong Bok Shin, Shin Myung Kang, Sun Young Kyung, Jeong-Woong Park, Sung Hwan Jeong, Eun Kyung Cho
Cancer Chemotherapy and Pharmacology.2014; 74(2): 277. CrossRef
Lung Cancer Screening
Young-Woong Won
Hanyang Medical Reviews.2014; 34(1): 15. CrossRef
Reply on "Characteristics and Survival of Korean Anal Cancer From the Korea Central Cancer Registry Data"
Hyoung-Chul Park, Bong Hwa Lee
Annals of Coloproctology.2014; 30(1): 56. CrossRef
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
Y-K Kang, S Y Rha, P Tassone, J Barriuso, R Yu, T Szado, A Garg, Y-J Bang
British Journal of Cancer.2014; 111(4): 660. CrossRef
Gender-specific Colorectal Cancer: Epidemiologic Difference and Role of Estrogen
Hee Man Kim, Hyun-Soo Kim
The Korean Journal of Gastroenterology.2014; 63(4): 201. CrossRef
Cancer Control Programs in East Asia: Evidence From the International Literature
Malcolm A. Moore
Journal of Preventive Medicine & Public Health.2014; 47(4): 183. CrossRef
Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in Korean and Taiwanese patients
Cheol Kwak, Tony Tong Lin Wu, Hyun Moo Lee, Hsi Chin Wu, Sung Joon Hong, Yen Chuan Ou, Seok Soo Byun, Hyou Young Rhim, Thian Kheoh, Ying Wan, Howard Yeh, Margaret K Yu, Choung Soo Kim
International Journal of Urology.2014; 21(12): 1239. CrossRef
Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity
Sea-Won Lee, Hong Seok Jang, Jong Hoon Lee, Sung Hwan Kim, Sei Chul Yoon
Medicine.2014; 93(28): e290. CrossRef
Economic Evaluation of Prostate Cancer Screening Test as a National Cancer Screening Program in South Korea
Sangjin Shin, Youn Hee Kim, Jin Sub Hwang, Yoon Jae Lee, Sang Moo Lee, Jeonghoon Ahn
Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3383. CrossRef
Reconsideration of Clinical and Histopathological Prognostic Factors in Breast Cancer Patients: A Single Center Experience
Ozgur Tanriverdi, Nezih Meydan, Sabri Barutca
Asian Pacific Journal of Cancer Prevention.2014; 15(2): 807. CrossRef
Differences in the Survival of Gastric Cancer Patients after Gastrectomy according to the Medical Insurance Status
Jae Seong Jang, Dong Gue Shin, Hye Min Cho, Yujin Kwon, Dong Hui Cho, Kyung Bok Lee, Sang Soo Park, Jin Yoon, Yong Seog Jang, Il Myung Kim
Journal of Gastric Cancer.2013; 13(4): 247. CrossRef

17,570 View
164 Download
100 Crossref

Review Article

Stereotactic Body Radiotherapy for Early Stage Lung Cancer: Yasushi Nagata; Cancer Res Treat. 2013;45(3):155-161. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.155

Abstract PDF PubReader ePub

Stereotactic body radiation therapy (SBRT) is a newly developed technique currently in clinical use. SBRT originated from stereotactic radiosurgery for intracranial tumors. SBRT has been widely used clinically for lung cancer. The practice of SBRT demands different kinds of patient fixation, breathing control, target determination, treatment planning, and verifications. The history and current standard technique are reviewed. Clinical studies of lung cancer showed high local control rates with acceptable toxicities. Past and on-going clinical trials are reviewed.

Citations

Citations to this article as recorded by

Evaluating the linear accelerator accuracy: Integrating Winston-Lutz measurement method and mathematical calculations
Hsi-Ya Chao, Wen-Tyng Li, Chih-Chia Chang, Yuk-Wah Tsang
Radiation Physics and Chemistry.2024; 217: 111504. CrossRef
Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Pain Relief for Bone Metastases: A Systematic Review and Meta-Analysis
Xing Song, Jun Wei, Rui Sun, Wenjie Jiang, Yuan Chen, Yingjie Shao, Wendong Gu
International Journal of Radiation Oncology*Biology*Physics.2023; 115(4): 909. CrossRef
Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death
Chang W. Song, Eli Glatstein, Lawrence B. Marks, Bahman Emami, Jimm Grimm, Paul W. Sperduto, Mi-Sook Kim, Susanta Hui, Kathryn E. Dusenbery, L. Chinsoo Cho
International Journal of Radiation Oncology*Biology*Physics.2021; 110(1): 21. CrossRef
Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non–Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy
Jason Liu, Caressa Hui, Colton Ladbury, Thomas Waddington, Loretta Erhunmwunsee, Dan Raz, Jae Kim, Ravi Salgia, Stafford Chenery, Daryl Pearlstein, Amanda Schwer, Arya Amini
Clinical Lung Cancer.2021; 22(5): e678. CrossRef
Optimization of irradiation interval for fractionated stereotactic radiosurgery by a cellular automata model with reoxygenation effects
Daisuke Kawahara, Lin Wu, Yoichi Watanabe
Physics in Medicine & Biology.2020; 65(8): 085008. CrossRef
Effets de l’irradiation à haute dose sur la vascularisation : physiopathologie et conséquences cliniques
A. Nivet, M. Schlienger, P. Clavère, F. Huguet
Cancer/Radiothérapie.2019; 23(2): 161. CrossRef
Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors
Chang W. Song, Robert J. Griffin, Yoon-Jin Lee, Haeun Cho, Jewoo Seo, Inhwan Park, Hyun K. Kim, Do H. Kim, Mi-Sook Kim, Kathryn E. Dusenbery, L. Chinsoo Cho
Radiation Research.2019; 192(2): 159. CrossRef
Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo
Wonwoo Kim, Mi-Sook Kim, Hee-jong Kim, Eunjin Lee, Jae-hoon Jeong, Inhwan Park, Youn Kyoung Jeong, Won Il Jang
International Journal of Hyperthermia.2018; 34(3): 276. CrossRef
Focal exposure of limited lung volumes to high-dose irradiation down-regulated organ development-related functions and up-regulated the immune response in mouse pulmonary tissues
Bu-Yeo Kim, Hee Jin, Yoon-Jin Lee, Ga-Young Kang, Jaeho Cho, Yun-Sil Lee
BMC Genetics.2016;[Epub] CrossRef
Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization
Changhoon Song, Beom-Ju Hong, Seoyeon Bok, Chan-Ju Lee, Young-Eun Kim, Sang-Rok Jeon, Hong-Gyun Wu, Yun-Sang Lee, Gi Jeong Cheon, Jin Chul Paeng, David J. Carlson, Hak Jae Kim, G-One Ahn
International Journal of Radiation Oncology*Biology*Physics.2016; 95(3): 1022. CrossRef
The impact of emphysema on dosimetric parameters for stereotactic body radiotherapy of the lung
Satoru Ochiai, Yoshihito Nomoto, Yasufumi Yamashita, Tomoki Inoue, Shuuichi Murashima, Daisuke Hasegawa, Yoshie Kurita, Yui Watanabe, Yutaka Toyomasu, Tomoko Kawamura, Akinori Takada, Noriko Ii, Shigeki Kobayashi, Hajime Sakuma
Journal of Radiation Research.2016; 57(5): 555. CrossRef
Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery
Chang W. Song, Yoon-Jin Lee, Robert J. Griffin, Inhwan Park, Nathan A. Koonce, Susanta Hui, Mi-Sook Kim, Kathryn E. Dusenbery, Paul W. Sperduto, L. Chinsoo Cho
International Journal of Radiation Oncology*Biology*Physics.2015; 93(1): 166. CrossRef
Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor
Satoru Ochiai, Yoshihito Nomoto, Yasufumi Yamashita, Shuuichi Murashima, Daisuke Hasegawa, Yusuke Kurobe, Yutaka Toyomasu, Tomoko Kawamura, Akinori Takada, Noriko II
Journal of Radiation Research.2015; 56(6): 904. CrossRef
Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
Mi-Sook Kim, Wonwoo Kim, In Hwan Park, Hee Jong Kim, Eunjin Lee, Jae-Hoon Jung, Lawrence Chinsoo Cho, Chang W. Song
Radiation Oncology Journal.2015; 33(4): 265. CrossRef
Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non–Small-Cell Lung Cancer: Five-Year Mature Results
Yuta Shibamoto, Chisa Hashizume, Fumiya Baba, Shiho Ayakawa, Akifumi Miyakawa, Taro Murai, Taiki Takaoka, Yukiko Hattori, Ryuji Asai
Journal of Thoracic Oncology.2015; 10(6): 960. CrossRef
Radiobiological basis of SBRT and SRS
Chang W. Song, Mi-Sook Kim, L. Chinsoo Cho, Kathryn Dusenbery, Paul W. Sperduto
International Journal of Clinical Oncology.2014; 19(4): 570. CrossRef
Recent advances in radiation oncology
Yasushi Nagata
International Journal of Clinical Oncology.2014; 19(4): 563. CrossRef
Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer
Anthony J Berdis
Expert Opinion on Drug Discovery.2014; 9(2): 167. CrossRef
Radiation Oncology: Physics Advances that Minimize Morbidity
Ron R Allison, Rajen M Patel, Robert A McLawhorn
Future Oncology.2014; 10(15): 2329. CrossRef

12,113 View
112 Download
19 Crossref

Original Articles

Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases: Woo Young Kim, Suk-Joon Chang, Ki-Hong Chang, Jong-Hyuck Yoon, Jang Hee Kim, Byoung-Gie Kim, Duk-Soo Bae, Hee-Sug Ryu; Cancer Res Treat. 2009;41(1):24-28. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.24

Abstract PDF PubReader ePub

Purpose

The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors.

Materials and Methods

This study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively.

Results

The median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859).

Conclusion

Mitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.

Citations

Citations to this article as recorded by

2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells
Hosouk Joung, Hyunju Liu
Oncology Reports.2024;[Epub] CrossRef
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
Clinical Cancer Research.2022; 28(17): 3850. CrossRef
Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature
Bruna Cristine de Almeida, Laura Gonzalez dos Anjos, Andrey Senos Dobroff, Edmund Chada Baracat, Qiwei Yang, Ayman Al-Hendy, Katia Candido Carvalho
Biomedicines.2022; 10(10): 2567. CrossRef
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis
Alessandro Rizzo, Margherita Nannini, Annalisa Astolfi, Valentina Indio, Pierandrea De Iaco, Anna Myriam Perrone, Antonio De Leo, Lorena Incorvaia, Valerio Di Scioscio, Maria Abbondanza Pantaleo
Cancers.2020; 12(7): 1899. CrossRef
Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage
Dhara Patel, Elizabeth Handorf, Margaret von Mehren, Lainie Martin, Sujana Movva
Sarcoma.2019; 2019: 1. CrossRef
Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
E Sun Paik, Jae Hong Kang, Jihye Kim, Yeon-Joo Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
Obstetrics & Gynecology Science.2019; 62(2): 103. CrossRef
Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis
Su Hyun Chae, Seung-Hyuk Shim, Misoo Chang, Ah Young Choi, Gun Gu Kang, Sun Joo Lee, Soo-Nyung Kim
Gynecologic Oncology.2019; 154(3): 638. CrossRef
Clinicopathological Correlation of Uterine Corpus Tumors: A Study of 433 Cases
Divya Shekhar Shetty, Alka Vikas Gosavi, Prashant Shankarrao Murarkar, Kalpana Ranjitsingh Sulhyan
Indian Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis
Giorgio Bogani, Giovanni Fucà, Giuseppa Maltese, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Cono Scaffa, Ilaria sabatucci, Francesca Lecce, Francesco Raspagliesi, Domenica Lorusso
Gynecologic Oncology.2016; 143(2): 443. CrossRef
Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation
Jasmine Tan-Kim, Katherine A. Hartzell, Caryl S. Reinsch, Cristina H. O’Day, John S. Kennedy, Shawn A. Menefee, Terry A. Harrison
American Journal of Obstetrics and Gynecology.2015; 212(5): 594.e1. CrossRef
Successful removal of uterine leiomyosarcoma tumour thrombus propagating to the right atrium
Yu Hui Lim, Lui Shiong Lee, Chong Hee Lim, Ghee Kheng Chew
BMJ Case Reports.2015; : bcr2015213384. CrossRef
Lung Metastasis after an Eighteen-Years-Long Disease-Free Period since Uterine Leiomyosarcoma Diagnosis
M. Guazzaroni, D. Tosti, M. Rascioni, M. Mataloni, D. Citraro, G. Simonetti
Case Reports in Oncological Medicine.2014; 2014: 1. CrossRef
FIGO Staging for Uterine Sarcomas: Can the Revised 2008 Staging System Predict Survival Outcome Better?
Ga Won Yim, Eun Ji Nam, Sang Wun Kim, Young Tae Kim
Yonsei Medical Journal.2014; 55(3): 563. CrossRef
Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma
Philip Wong, Kathy Han, Jenna Sykes, Charles Catton, Stephane Laframboise, Anthony Fyles, Lee Manchul, Wilfred Levin, Michael Milosevic
Radiation Oncology.2013;[Epub] CrossRef
Uterine Sarcomas: Then and Now
Shaan H. Shah, Jyothi P. Jagannathan, Katherine Krajewski, Kevin N. O???Regan, Suzanne George, Nikhil H. Ramaiya
American Journal of Roentgenology.2012; 199(1): 213. CrossRef
Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma
V. Loizzi, G. Cormio, D. Nestola, M. Falagario, A. Surgo, A. Camporeale, G. Putignano, L. Selvaggi
Oncology.2011; 81(2): 91. CrossRef
Surgical treatment of uterine sarcoma
Joo-Hyun Nam
Best Practice & Research Clinical Obstetrics & Gynaecology.2011; 25(6): 751. CrossRef
The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma
Jeong-Yeol Park, Sun-Kyung Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Gynecologic Oncology.2011; 122(2): 255. CrossRef
Co-existence of three rare gynecological tumors in a 79-year-old woman
Hongkai Zhang, Melinda Lerwill
Archives of Gynecology and Obstetrics.2011; 284(3): 695. CrossRef

10,586 View
61 Download
19 Crossref

The Effect of Adjuvant Chemotherapy on Stage IV (T4N1-3M0 and T1-3N3M0) Gastric Cancer: Tae Kyung Ha, Min Sung Jung, Kang Hong Lee, Kyeong Geun Lee, Sung Joon Kwon; Cancer Res Treat. 2009;41(1):19-23. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.19

Abstract PDF PubReader ePub

Purpose

The optimal chemotherapeutic strategy for gastric cancer patients has not been determined, especially with respect to stage and the curability of gastric cancer. The aim of this study was to evaluate the results of adjuvant chemotherapy on stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer after curative gastrectomy between a chemotherapy (CTX) group and non-chemotherapy (non-CTX) group.

Materials and Methods

Among 1,760 patients who underwent gastric surgery by 1 surgeon in a single institution, 162 stage IV gastric cancer patients with curative gastrectomy were analyzed retrospectively, excluding patients with TanyNanyM1. One hundred twenty-five patients who received different chemotherapeutic regimens were compared to 37 patients who did not receive chemotherapy for reasons of old age or according to their expressed desire.

Results

The clinicopathologic factors which showed a clinically significant difference between the two groups were age and histology, which were not associated with patient survival. The CTX group was younger, and had a larger proportion of undifferentiated gastric cancers than the non-CTX group. The mode of treatment failure revealed no significant difference between the CTX and non-CTX groups. The 1, 3, and 5-year disease-free survival and the 1, 3, and 5-year disease-specific survival of the CTX group were 63.9%, 38.4%, and 32.0%, and 85.4%, 52.3%, and 39.6%, respectively, which were more favorable than the non-CTX group (p=0.015 and p=0.001, respectively). Postoperative adjuvant CTX was an independent risk factor for disease-specific survival of stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer patients after curative gastrectomy by multivariate analysis (odds ratio=2.153; 95% confidence interval=1.349-3.435; p=0.001).

Conclusions

Adjuvant CTX may be associated with survival benefit for younger patients with stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer with undifferentiated histology after curative gastrectomy. A randomized controlled trial to reveal the effect of stage-specific adjuvant chemotherapy should be conducted.

Citations

Citations to this article as recorded by

Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer
Qi-Wei Wang, Xiao-Tian Zhang, Ming Lu, Lin Shen
World Journal of Gastrointestinal Oncology.2018; 10(1): 31. CrossRef
Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis
Jisen Cao, Feng Qi, Tong Liu
Scandinavian Journal of Gastroenterology.2014; 49(6): 690. CrossRef

9,992 View
42 Download
2 Crossref

Treatment Outcome of Limited Stage Hodgkin's Disease: Jung Hun Kang, Yong Chan Ahn, Won Seog Kim, Won Ki Kang; Cancer Res Treat. 2005;37(1):31-36. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.31

Abstract PDF PubReader ePub: Purpose
The 10-year overall survival rate following conventional treatments for patients with limited-stage Hodgkin's disease (HD) exceeds 90%. However, the clinical features and treatment outcome of HD in Korea have not been extensively characterized due to its low incidence. In this study, we attempted to analyze the treatment outcome of different modalities in limited stage HD patients.
Materials and Methods
Twenty one Hodgkin's disease patients, referred to the Samsung Medical Center between January 1997 and December 2003, were enrolled in this study. Limited stage Hodgkin's disease was subdivided into low and high risk groups. All evaluable patients received treatment.
Results
There were 13 and 8 patients in the low and high risk groups, respectively. Eighteen patients (86%) obtained complete response (CR) and 3 patients (14%) achieved an undetermined complete response (CRu). Fourteen (67%), 4 (19%) and 3 (14%) cases received combination chemotherapy, radiotherapy alone and chemotherapy alone, respectively. Four cases relapsed and 2 obtained a second CR. The 5-year overall and disease-free survival rates were 90 and 72%, respectively, for all patients. The median follow-up duration was 31 months. There was no difference in disease free survival (DFS) between the low and high risk groups. Although 12 cases had neutropenia greater than grade III, none experienced neutropenic fever.
Conclusion
The treatment outcome of limited-stage HD was excellent, regardless to the initial treatment modality.

7,805 View
42 Download

Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia: Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park; Cancer Res Treat. 2005;37(1):20-23. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.20

Abstract PDF PubReader ePub

Purpose

This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.

Materials and Methods

A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).

Results

Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.

Conclusion

The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by

Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test
Kyle S. Liu, Rollin George, Caleb Shin, Jia Q. Xiong, Taher Jamali, Yan Liu, Priya Roy, Sonia Singh, Samuel Ma, Hashem B. El-Serag, Mimi C. Tan
Digestive Diseases and Sciences.2025; 70(1): 350. CrossRef
Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef
Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
Middle East Journal of Digestive Diseases.2022; 14(4): 382. CrossRef
Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
Annals of Surgical Treatment and Research.2021; 100(3): 154. CrossRef
Screening for Colorectal Cancer
Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
JAMA.2021; 325(19): 1978. CrossRef
Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
Cancers.2021; 13(17): 4481. CrossRef
Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190. CrossRef
Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
American Journal of Gastroenterology.2020; 115(1): 56. CrossRef
Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
Clinical Gastroenterology and Hepatology.2020; 18(13): 2920. CrossRef
Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
Annals of Internal Medicine.2019; 170(5): 319. CrossRef
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
Gastroenterology.2019; 157(6): 1494. CrossRef
Quantitative fecal immunochemical tests for colorectal cancer screening
Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
International Journal of Cancer.2018; 143(2): 234. CrossRef
Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
Lupus.2018; 27(5): 788. CrossRef
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Gut and Liver.2018; 12(2): 183. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastroenterology.2017; 152(5): 1217. CrossRef
Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastrointestinal Endoscopy.2017; 85(1): 2. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
American Journal of Gastroenterology.2017; 112(1): 37. CrossRef
Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
Journal of Clinical Gastroenterology.2017; 51(2): 151. CrossRef
Which Fecal Immunochemical Test Should I Choose?
Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
Journal of Primary Care & Community Health.2017; 8(4): 264. CrossRef
Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
Biomarkers in Medicine.2017; 11(8): 629. CrossRef
Screening of colorectal cancer: present and future
Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
Expert Review of Anticancer Therapy.2017; 17(12): 1131. CrossRef
Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Journal of Clinical Gastroenterology.2017; 51(9): 825. CrossRef
Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
Digestive Diseases and Sciences.2013; 58(11): 3256. CrossRef
Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
Digestive Diseases and Sciences.2012; 57(8): 2178. CrossRef
A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
Scandinavian Journal of Gastroenterology.2012; 47(4): 461. CrossRef
Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
Journal of the Korean Society of Coloproctology.2010; 26(6): 420. CrossRef
The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
Intestinal Research.2010; 8(2): 126. CrossRef
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
International Journal of Cancer.2009; 125(4): 746. CrossRef
Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
British Journal of Cancer.2009; 101(8): 1274. CrossRef
Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
Gastroenterology.2008; 135(1): 82. CrossRef

11,039 View
89 Download
31 Crossref

Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea: Se Hoon Lee, Hee Jeoung Cha, Jee Hyun Kim, Im Il Na, Jun Hee Lee, Hark Kyun Kim, Keun Seok Lee, Won Sup Lee, Chong Jai Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(6):1022-1030.

Abstract PDF: PURPOSE
The clinicopathologic features and prognostic factors of gastrointestinal leiomyosarcoma have been a source of controversy.
MATERIALS AND METHODS
A retrospective study was made of 91 incident cases of gastrointestinal leiomyosarcoma from 1979 to 1998 to identify clinicopathologic features and prognostic factors.
RESULTS
The median age of study subjects was 56 years and 58.2% was male. Tumors consisted of 2 esophagus, 39 stomach, 38 small bowel, 12 large bowel leiomyosarcoma. Mean size of the tumors was 10.9 cm and 52.9% of them was larger than 10 cm. The tumors were classified as localized stage (42 cases), advanced stage (21 cases), and metastatic stage (28 cases). Again, the tumors were classified as low grade (48 cases) and high grade (18 cases). Median overall survival was 37.4 months and median disease-free survival was 28.2 months. In univariate analysis, the significant factors affecting the overall survival of patients with leiomyosarcoma were stage, size greater than 10 cm, performance status, and histologic grade. In multivariate analysis, stage, performance status, and histologic grade were independent factors affecting the overall survival. In univariate analysis, the significant factors affecting the disease-free survival were stage, performance status, and histologic grade. In multivariate analysis, histologic grade was the only independent factor affecting the disease-free survival.
CONCLUSION
Stage, performance status, and histologic grade were independent factors affecting the overall survival. Histologic grade was independent factor affecting the disease-free survival.

2,809 View
14 Download

Results of Radio-thermotherapy in Stage IIIb Uterine Cervical Cancer Local response, survival rate and analysis of prognostic factor: Chang Woo Moon; J Korean Cancer Assoc. 2000;32(4):714-723.

Abstract PDF: PURPOSE
This retrospective study was conducted to obtain local response and survival rates, and to analyze prognostic factors affecting survival of patients treated with radio-thermotherapy for stage IIIb uterine cervical cancer.
MATERIALS AND METHODS
From May 1992 to Dec. 1996, 24 patients treated with radio-thermo therapy for stage IIIb uterine cervical cancer at department of Radiation Oncology in Kosin Medical College, Kosin University were enrolled. Radiotherapy used 6~10 MV linear accelerator was performed in whole pelvis with 4 portals box technique by conventional (180~200 cGy/ fraction, 5 fraction/week) method in 5 patients (20.8%) or hyperfractionated (120~135 cGy/fr., 2 fr./day, 10 fr./wk) in 19 patients (79.2%). Total dose of A-point was 67~112 Gy (median: 77.27 Gy). Hyperthermia used 8 MHz radiofrequency capacitive heating device was applied in pelvic area with 2~3 sessions per wk. Each course started within 15 to 20 minutes after radio therapy and took 40 to 60 minutes. Local progression free (LPFS), disease free (DFS) and overall (OS) rates were calculated in survival analysis. Statistics was calculated by Kaplan-Meier Method in survival and Log-rank test in statistical significance. Multivariate analysis for prognostic factor was applied to Cox Regression model. Follow-up duration was 6~82 months (median: 25 months).
RESULTS
Overall local response rate was 95.8% (45.8% in CR/50.0% in PR). Five year LPFS, DFS, OS were 48.6%, 31.7%, 67.1%, respectively. In univariate analysis, an age was the signi ficant prognostic factor in terms of OS (p=0.03), but was insignificant in LPFS and DFS. In multivariate analysis, none of evaluated factors are important in LPFS, DFS or OS.
CONCLUSION
Radio-thermotherapy for stage IIIb uterine cervical cancer did not increase 5 year LPFS, DFS and OS in spite of higher local response rate. Age was the only significant factor for OS in univariate analysis.

2,315 View
15 Download

Diagnostic Value of MRI in the T Staging of Colorectal Carcinoma: B C Kang, S W Lee, S Y Baek, H Y Choi, S Lee; J Korean Cancer Assoc. 2000;32(2):321-330.

Abstract PDF: PURPOSE
We studied to determine the usefulness of magnetic resonance imaging (MRI) in the preoperative T-staging of colorectal cancer.
MATERIALS AND METHODS
Twenty patients with colon cancer and S patients with rectosigmoid neoplasm, who were diagnosed between October 1997 and June 1998 by barium enema, colono-scopic biopsy were evaluated. Patients consisted of 16 men and 12 women, with ages ranging from 46 to 68 years (mean 61 years). Preoperative staging was done with MRI. We used 2D-FLASH (Fast Low-Angle Shot), FISP (Fast-Imaging Shot-angle Precession), and Turbo-SE (Spin-Echo) sequences. Acquisition time of these MR techniques was 13~15 sec. 2D-FLASH MRI after intravenous injection of 0.1 mmol/kg Gd-DTPA were obtained for the dynamic and delayed enhanced MR images. Preoperative stages of MRI were decided with a consensus by two radiologists. Pathologic stages were done by TNM classification.
RESULTS
T-stages determined by enhanced 2D-FLASH MR images of colorectal cancer were correlated with histopathologic findings in 2 of 3 pT2 (pathologic T2) tumor (67%), 17 of 21 pT3 (81%), and 4 of 4 pT4 tumors (100%). T-stages determined by FISP were correlated with histopathologic findings in 2 of 3 pT2 tumor (67%), 16 of 21 pT3 (76%), and 3 of 4 pT4 tumors (75%), and T-stages by Turbo-SE were correlated in 2 of 3 pT2 tumor (67%), 18 of 21 pT3 (86%), and 3 of 4 pT4 tumors (75%). MRI correctly diagnosed tumor deposits of involved lymph nodes in 16 patients, overall accuracy was 57% (16/28%). Signal intensity between the cancerous and normal wall was not significantly different on MRI using FISP (P>0.05). But, that was significantly different on the MRI using Turbo-SE (p<0.05), CONCLUSION: Fast MR sequences has a role for the preoperative T-staging of colorectal neoplasm.

2,339 View
31 Download

A Study of Relationship between the Progression and Subtypes of Gastric Adenocarcinoma and Fas - L / sFas - L: S C Lim, Y D Min; J Korean Cancer Assoc. 2000;32(2):288-296.

Abstract PDF: PURPOSE
The purpose of this study is to determine whether human gastric adenocarcinoma expresses Fas-L, whether serum sFas-L level is changed in patients before and after gastrectomy, and whether Fas-L or sFas-L is concerned in tumor stage and histologic type.
MATERIALS AND METHODS
The authors analysed 38 cases of early gastric carcinoma (EGC) and 61 cases of advanced gastric carcinoma (AGC) who received gastric resection from 1997 to 1998, in whom the number of diffuse type is 38 cases and the number of intestinal type is 61 cases. The authors used immunohistochemical staining for tumoral Fas-L detection and sFas ligand ELISA kit for serum sFas-L detection.
RESULTS
Fas-L was localized to neoplastic cells in 61% (23/38) cases of EGC group and 66% (40/61) cases of AGC group. The extent of Fas-L expression was variable, with both FasL- positive and -negative neoplastic region occuring within tumors. The mean serum sFas-L level was highly significantly higher in patients before treatment compared with controls, whereas in patients in post-gastrectomy was significantly lower as the level of controls. Some patients whose preoperative serum sFas-L levels were within normal limits expressed no tumoral Fas-L. In addition, factors such as tumor stage, histologic subtype and other prognostic factors were not concerned in Fas-L expression and serum sFas-L level.
CONCLUSION
The authors demonstrate a statistically significant expression of tumoral Fas-L with concomitant increment of serum sFas-L in gastric adenocarcinoma. This finding suggests Fas-mediated apoptosis in response to Fas-L expression by gastric adenocarcinoma, and provide the evidence to support the Fas counterattack and indicate that the serum sFas-L level is a useful indicator in evaluating preoperative diagnosis and postoperative follow-up of gastric adeno- carcinoma. In addition, every clinical stages of gastric adenocarcinoma of the intestinal and the diffuse type not differ in their expression of the Fas and sFas-L.

2,185 View
13 Download

Korean Breast Cancer Data of 1997: J Korean Cancer Assoc. 1999;31(6):1202-1209.

Abstract PDF: PURPOSE
In Korea, breast cancer is the third most common cancer in female following uterine cervix cancer, stomach cancer, and the incidence is increasing year by year.
MATERIALS AND METHODS
In 1997, the Korean Breast Cancer Society collected the data of new breast cancer patients who were treated at 35 university hospitals and 16 general hospitals nationwidely.
RESULTS
Total patients were 4,168 cases, female of 4,149 (99.5%) and male of 19 (0.5%) cases. Age distribution showed that there were 2 cases (0.05%) in 10~19 years of age, 109 cases (2.6%) in 20~29 years, 878 cases (21.1%) in 30~39 years, 1,504 cases (36.1%) in 40~49 years, 1,090 cases (26.1%) in 50~59 years, 431 cases (10.3%) in 60~69 years, 128 cases (3.1%) in 70~79 years, 25 cases (0.6%) in 80 years or above, 1 case of unknown. A radical mastectomy was performed in 50 cases (1.2%), a modified radical mastectomy in 3,094 cases (74.2%), a simple mastectomy m 114 cases (2.7%), a breast conserving surgery in 740 cases (17.8%), segmentectomy or excision in 86 cases (2.1%), biopsy or etc. in 81 cases (1.9%), and unkown in 3 cases (0.1%). According to the TNM staging system, there were 188 (4.8%) with stage 0, 849 (21.7%) with stage I, 1,344 (34.3%) with stage IIA, 810 (20.7%) with stage IIB, 415 (10.6%) with stage IIIA, 106 (2.7%) with stage IIIB, and 83 (2.1%) with stage IV.
CONCLUSION
We, all the members of the Korean Breast Cancer Society believe that it is very important to join the nationwide collection of Korean breast cancer data since 1996 when the first nationwide baseline data was reported, and we think that we have been accomplishing the purposes of study, which is to report the yearly natiowide data of Korean breast cancer, and to compare our data with those of other countries.

2,578 View
18 Download

First
Prev
Page of 2
Next
Last

Search